http://www.pharmajournalist.com/gilead-and-merus-announce-collaboration-to-discover-novel-antibody-based-trispecific-t-cell-engagers/ 2024-03-08T12:58:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gilead.jpg http://www.pharmajournalist.com/johnson-johnson-submits-application-to-the-european-medicines-agency-for-darzalex-daratumumab-based-quadruplet-therapy-for-the-treatment-of-patients-with-transplant-eligible-newly-diagnosed-multi/ 2024-03-08T13:01:26+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/sandoz-receives-fda-approval-for-first-and-only-denosumab-biosimilars/ 2024-03-08T13:03:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/almirall-and-eloxx-pharmaceuticals-enter-into-exclusive-agreement-to-license-zkn-013-for-rare-dermatological-diseases/ 2024-03-14T14:54:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/Almirall_Plant_Reinbek.jpg http://www.pharmajournalist.com/european-commission-approves-pfizers-prevenar-20-to-help-protect-infants-and-children-against-pneumococcal-disease/ 2024-03-14T14:56:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/merck-announces-plans-to-conduct-clinical-trials-of-a-novel-investigational-multi-valent-human-papillomavirus-hpv-vaccine-and-single-dose-regimen-for-gardasil9/ 2024-03-14T14:58:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/merck-group.jpg http://www.pharmajournalist.com/pearl-bio-inks-collaboration-with-merck-to-discover-novel-engineered-biologics/ 2024-03-14T15:01:47+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/johnson-johnson-submits-supplemental-biologics-license-application-to-u-s-fda-seeking-approval-of-tremfya-guselkumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-coli/ 2024-03-14T15:03:27+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/tierra-biosciences-secures-11-4m-series-a-funding-round-led-by-material-impact/ 2024-03-14T15:04:45+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/merck-completes-acquisition-of-harpoon-therapeutics-inc/ 2024-03-14T15:05:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-and-pediatric-exclusivities-for-cresemba-isavuconazonium-sulfate-for-invasive-aspergillosis-and-invasive-mucormycosis-in-children/ 2024-03-14T15:07:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/novartis-expands-its-biopharmaceutical-manufacturing-site-in-singapore/ 2024-03-19T00:34:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/fda-oncologic-drugs-advisory-committee-recommends-carvykti-ciltacabtagene-autoleucel-for-the-earlier-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/ 2024-03-19T00:36:29+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/next-gen-peptide-formulation-delivery-summit-unleash-peptide-potential-through-cutting-edge-delivery-innovations/ 2024-03-19T13:42:58+00:00 https://pharmajournalist.com/wp-content/uploads/2024/03/34697-PharmaJournalist.png http://www.pharmajournalist.com/bristol-myers-squibbs-abecma-idecabtagene-vicleucel-becomes-first-car-t-cell-therapy-approved-in-the-european-union-in-earlier-lines-for-triple-class-exposed-relapsed-and-refractory-multipl/ 2024-03-21T10:10:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/lonza-signs-agreement-to-acquire-large-scale-biologics-site-in-vacaville-us-from-roche/ 2024-03-21T10:11:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/Lonza.jpg http://www.pharmajournalist.com/fda-approves-edurant-ped-rilpivirine-for-certain-pediatric-patients-living-with-hiv-1/ 2024-03-21T10:13:38+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/spevigo-approved-for-expanded-indications-in-china-and-the-us/ 2024-03-21T10:15:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/astrazeneca-to-acquire-fusion-to-accelerate-the-development-of-next-generation-radioconjugates-to-treat-cancer/ 2024-03-21T10:17:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/bristol-myers-squibb-completes-acquisition-of-karuna-therapeutics-strengthening-neuroscience-portfolio/ 2024-03-21T10:18:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/orchard-therapeutics-receives-fda-approval-of-lenmeldy-atidarsagene-autotemcel-the-only-therapy-for-eligible-children-with-early-onset-metachromatic-leukodystrophy-in-the-u-s/ 2024-03-21T10:20:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/eisai-to-divest-rights-for-merislon-and-myonal-in-japan-to-kaken-pharmaceutical/ 2024-04-02T22:12:47+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/EISAI.jpg http://www.pharmajournalist.com/voydeya-approved-in-the-us-as-add-on-therapy-to-ravulizumab-or-eculizumab-for-treatment-of-extravascular-haemolysis-in-adults-with-the-rare-disease-pnh/ 2024-04-02T22:14:12+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Alexion-Pharma-Logo.png http://www.pharmajournalist.com/eisai-completes-submission-of-leqembi-lecanemab-irmb-supplemental-biologics-license-application-for-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-to-the-u-s-fda/ 2024-04-02T22:15:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/EISAI.jpg http://www.pharmajournalist.com/gilead-and-xilio-announce-exclusive-license-agreement-for-tumor-activated-il-12-program/ 2024-04-02T22:18:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/solid-biosciences-receives-rare-pediatric-disease-designation-from-the-fda-for-duchenne-muscular-dystrophy-gene-therapy-candidate-sgt-003/ 2024-04-02T22:21:18+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/solid-biosciences.jpg http://www.pharmajournalist.com/nurix-therapeutics-announces-extension-of-strategic-collaboration-with-gilead-sciences/ 2024-04-02T22:24:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/trevi-therapeutics-adds-clinical-development-expertise-in-chronic-cough-to-leadership-team/ 2024-04-02T22:26:02+00:00 https://pharmajournalist.com/wp-content/uploads/2019/02/trevi-therapeutics-logo.png http://www.pharmajournalist.com/shorla-oncology-announces-fda-filing-acceptance-of-new-drug-application-to-treat-certain-forms-of-leukemia-and-other-cancers/ 2024-04-09T13:22:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-u-s-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy/ 2024-04-09T13:25:23+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/fda-approves-bristol-myers-squibb-and-2seventy-bios-abecma-for-triple-class-exposed-relapsed-or-refractory-multiple-myeloma-after-two-prior-lines-of-therapy/ 2024-04-09T13:28:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/medicxi-and-starpharma-create-petalion-therapeutics-to-develop-novel-dendrimer-based-treatments-asx-announcement/ 2024-04-09T13:30:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/enhertu-approved-in-the-us-as-first-tumour-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumours/ 2024-04-09T13:31:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/imfinzi-significantly-improved-overall-survival-and-progression-free-survival-for-patients-with-limited-stage-small-cell-lung-cancer-in-adriatic-phase-iii-trial/ 2024-04-09T13:33:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/neurosense-collaborates-with-lonza-to-identify-exosome-based-biomarkers-in-order-to-advance-neurodegenerative-disease-treatments-and-diagnostics/ 2024-04-10T11:20:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/lonza.jpg http://www.pharmajournalist.com/pfizer-announces-positive-top-line-results-from-phase-3-study-of-abrysvo-in-adults-aged-18-to-59-at-increased-risk-for-rsv-disease/ 2024-04-10T11:22:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/bayer-and-google-cloud-to-accelerate-development-of-ai-powered-healthcare-applications-for-radiologists/ 2024-04-10T11:24:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/neumora-therapeutics-announces-clinical-hold-of-phase-1-nmra-266-study/ 2024-04-16T12:15:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-soligenix-orphan-drug-designation-for-the-prevention-and-post-exposure-prophylaxis-against-marburg-marburgvirus-infection/ 2024-04-16T12:20:03+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/soligenix-logo.jpg http://www.pharmajournalist.com/innate-pharma-announces-advancement-of-sanofi-developed-nk-cell-engager-sar443579-iph6101-progressing-to-phase-2-for-blood-cancer-patients/ 2024-04-16T12:21:48+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/igm-biosciences-announces-refocusing-of-sanofi-collaboration/ 2024-04-19T09:37:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/05/igm-biosciences.jpg http://www.pharmajournalist.com/outrun-therapeutics-launches-with-a-10m-seed-financing-from-m-ventures-and-mp-healthcare-venture-management-to-develop-a-protein-stabilisation-pipeline/ 2024-04-19T09:38:26+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/clearmind-medicine-announces-exclusive-licensing-agreement-for-generation-3-0-psychedelic-compounds-for-the-treatment-of-mental-disorders/ 2024-04-19T09:40:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/essential-pharma-announces-the-acquisition-of-reminyl-galantamine-hydrobromide-oral-capsules/ 2024-04-19T09:41:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/vertex-announces-advancements-of-suzetrigine-vx-548-in-acute-and-neuropathic-pain/ 2024-04-19T09:54:24+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/evotec-and-variant-bio-enter-strategic-partnership-to-discover-and-develop-fibrosis-treatments/ 2024-04-19T09:56:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/trilink-biotechnologies-announces-new-san-diego-facility-for-late-phase-mrna-drug-substance-production/ 2024-04-19T10:02:56+00:00 https://pharmajournalist.com/wp-content/uploads/2024/04/TriLink-New-San-Diego-Facility.png https://pharmajournalist.com/wp-content/uploads/2024/04/TriLink-New-San-Diego-Facility.png http://www.pharmajournalist.com/ochre-bio-announces-partnership-with-boehringer-ingelheim-to-develop-novel-regenerative-treatments-for-patients-with-advanced-liver-disease/ 2024-04-23T15:00:36+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer/ 2024-04-23T15:02:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ipsen-and-skyhawk-therapeutics-announce-rna-targeting-research-collaboration-in-rare-neurological-diseases/ 2024-04-23T15:03:47+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/european-commission-approves-pfizers-emblaveo-for-patients-with-multidrug-resistant-infections-and-limited-treatment-options/ 2024-04-23T15:05:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/rilzabrutinib-luna-3-phase-3-study-met-primary-endpoint-in-immune-thrombocytopenia/ 2024-04-23T15:07:06+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/merck-invests-more-than-e-300-million-in-new-life-science-research-center-in-germany/ 2024-04-26T11:14:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/regeneron-and-mammoth-biosciences-collaborate-to-pursue-next-generation-crispr-based-gene-editing-for-multiple-diseases/ 2024-04-26T11:15:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/novartis-radioligand-therapy-lutathera-fda-approved-as-first-medicine-specifically-for-pediatric-patients-with-gastroenteropancreatic-neuroendocrine-tumors/ 2024-04-26T11:17:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/incyte-announces-acquisition-of-escient-pharmaceuticals-and-its-pipeline-of-first-in-class-oral-mrgpr-antagonists/ 2024-04-26T11:20:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/incyte-logo.jpg http://www.pharmajournalist.com/johnson-johnson-submits-regulatory-applications-to-european-medicines-agency-for-tremfya-guselkumab-for-treatment-of-patients-with-ulcerative-colitis-and-crohns-disease/ 2024-05-02T13:13:15+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/fda-approves-high-concentration-citrate-free-formulation-of-cyltezo-adalimumab-adbm-injection-boehringer-ingelheims-interchangeable-biosimilar-to-humira/ 2024-05-02T13:14:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/neurocrine-biosciences-announces-fda-approval-of-ingrezza-sprinkle-valbenazine-capsules/ 2024-05-02T13:16:58+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Neurocrine-Biosciences.jpg http://www.pharmajournalist.com/janssen-to-adopt-johnson-johnson-brand-as-the-company-celebrates-100-years-of-operating-in-the-uk/ 2024-05-02T13:18:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Janssen-Pharma-Logo.jpg http://www.pharmajournalist.com/enlaza-therapeutics-raises-100-million-through-its-series-a-financing-led-by-the-life-sciences-group-of-j-p-morgan-private-capital/ 2024-05-02T13:20:29+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/bayer-and-evotec-collaborate-to-advance-precision-cardiology/ 2024-05-02T13:21:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/novartis-enters-agreement-to-acquire-mariana-oncology-strengthening-radioligand-therapy-pipeline/ 2024-05-02T13:22:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/aspaveli-pegcetacoplan-approved-in-europe-for-use-among-treatment-naive-adult-patients-with-pnh/ 2024-05-09T10:02:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/sobi.jpg http://www.pharmajournalist.com/anixa-biosciences-expands-partnership-with-cleveland-clinic-to-develop-additional-cancer-vaccines/ 2024-05-09T10:04:06+00:00 https://pharmajournalist.com/wp-content/uploads/2021/02/anixa-biosciences-logo.png http://www.pharmajournalist.com/iecure-receives-fda-fast-track-designation-for-ecur-506-for-the-treatment-of-neonatal-onset-ornithine-transcarbamylase-otc-deficiency/ 2024-05-09T10:05:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/bioversys-announces-expansion-of-strategic-collaboration-with-gsk-and-extension-of-its-series-c-round-by-chf-12-3-million/ 2024-05-09T10:07:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/astrazeneca-completes-equity-investment-agreement-with-cellectis/ 2024-05-09T10:08:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/cytomx-therapeutics-announces-positive-initial-phase-1a-dose-escalation-data-for-monotherapy-cx-904-egfrxcd3-probody-t-cell-engager/ 2024-05-09T10:11:31+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Cytomx-Logo.jpg http://www.pharmajournalist.com/sanofi-and-novavax-announce-co-exclusive-licensing-agreement-to-co-commercialize-covid-19-vaccine-and-develop-novel-flu-covid-19-combination-vaccines/ 2024-05-13T10:38:24+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/shionogi-co-ltd-and-maze-therapeutics-inc-announce-exclusive-worldwide-license-agreement-for-mze001-a-novel-therapeutic-candidate-for-the-treatment-of-pompe-disease/ 2024-05-13T10:40:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/kite-and-arcellx-continue-momentum-with-advances-in-anito-cel-multiple-myeloma-program/ 2024-05-13T10:43:03+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/ribobay-pharma-boosts-crdmo-offerings-with-cytivas-first-flexfactory-platform-for-oligonucleotides/ 2024-05-13T10:46:53+00:00 https://pharmajournalist.com/wp-content/uploads/2024/05/Ribobay_Pharma_s_site_in_Anhui.jpg https://pharmajournalist.com/wp-content/uploads/2024/05/Ribobay_Pharma_s_site_in_Anhui.jpg http://www.pharmajournalist.com/westgenes-mrna-therapeutic-cancer-vaccine-receives-fda-approval/ 2024-05-13T10:48:36+00:00 https://pharmajournalist.com/wp-content/uploads/2024/05/WestGene.jpg http://www.pharmajournalist.com/flagship-pioneering-and-metaphore-biotechnologies-announce-research-collaboration-with-novo-nordisk-to-develop-next-generation-therapeutics-for-obesity-management/ 2024-05-13T10:49:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/nabla-bio-secures-26m-series-a-financing-and-collaborations-with-astrazeneca-bristol-myers-squibb-and-takeda-for-generative-protein-design/ 2024-05-15T10:06:38+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/abbvie-and-gilgamesh-pharmaceuticals-announce-collaboration-and-option-to-license-agreement-to-develop-next-generation-therapies-for-psychiatric-disorders/ 2024-05-15T10:07:54+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/moffitt-cancer-center-and-fulgent-pharma-join-forces-to-revolutionize-cancer-therapeutics/ 2024-05-15T10:10:11+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/astrazeneca-plans-1-5-billion-manufacturing-facility-for-antibody-drug-conjugates-adcs-in-singapore/ 2024-05-22T15:50:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/genmab-completes-acquisition-of-profoundbio/ 2024-05-22T15:58:35+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/Genmab-Logo.jpg http://www.pharmajournalist.com/alvotech-and-dr-reddys-enter-into-collaboration-for-commercialization-of-avt03-denosumab-a-biosimilar-candidate-to-prolia-xgeva-in-the-u-s-europe-and-uk/ 2024-05-22T16:00:50+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/altrubio-secures-up-to-225m-oversubscribed-series-b-financing-to-advance-the-clinical-development-of-novel-immune-checkpoint-enhancer-program/ 2024-05-22T16:03:32+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/sanofi-formation-bio-and-openai-announce-first-in-class-ai-collaboration/ 2024-05-22T16:04:45+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/fda-grants-breakthrough-therapy-designation-to-genentechs-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation/ 2024-05-22T16:07:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/Genentech-Image.jpg http://www.pharmajournalist.com/nona-biosciences-announces-global-license-and-option-agreement-with-astrazeneca-for-monoclonal-antibody-to-be-developed-into-novel-tumor-targeted-therapies/ 2024-05-23T11:29:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/sandoz-receives-european-commission-approval-for-wyost-and-jubbonti-the-first-and-only-biosimilars-of-denosumab-in-europe/ 2024-05-23T11:31:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/biogen-bolsters-late-stage-pipeline-expands-immunology-portfolio-with-agreement-to-acquire-human-immunology-biosciences/ 2024-05-23T11:33:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/celltrion-receives-european-commission-approval-of-omlyclo-ct-p39-the-first-and-only-omalizumab-biosimilar-approved-in-europe/ 2024-05-24T11:47:50+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/celltrion-Image.png http://www.pharmajournalist.com/4th-next-generation-gene-therapy-vectors-summit-countdown-begins/ 2024-05-29T09:04:37+00:00 https://pharmajournalist.com/wp-content/uploads/2024/04/4th-Next-Generation-Gene-Therapy-Vectors-Summit.jpg https://pharmajournalist.com/wp-content/uploads/2024/04/4th-Next-Generation-Gene-Therapy-Vectors-Summit.jpg http://www.pharmajournalist.com/merck-launches-first-software-for-complete-data-traceability-in-microbial-qc/ 2024-05-29T09:07:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/johnson-johnson-to-obtain-rights-to-a-clinical-stage-bispecific-antibody-to-address-distinct-patient-needs-in-atopic-dermatitis/ 2024-05-29T09:10:48+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/sarclisa-accepted-for-fda-priority-review-for-the-treatment-of-transplant-ineligible-newly-diagnosed-multiple-myeloma/ 2024-05-29T09:13:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/merck-to-acquire-eyebio/ 2024-05-30T08:13:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-meta/ 2024-05-30T08:17:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-roches-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation/ 2024-05-30T08:19:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/hanall-biopharma-signs-licensing-agreement-with-turn-biotechnologies-to-develop-novel-treatments-for-eye-and-ear-diseases/ 2024-05-30T08:22:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/i-mab-announces-collaboration-with-bristol-myers-squibb-to-evaluate-givastomig-in-a-combination-study-for-newly-diagnosed-gastric-and-esophageal-cancers/ 2024-06-06T11:07:35+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/I-MAB-Biopharma-Logo.jpg http://www.pharmajournalist.com/alphamab-oncology-collaborated-with-arrivent-in-relation-to-the-research-development-and-commercialization-of-adc-products/ 2024-06-06T11:08:54+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/acquisition-of-fusion-completed/ 2024-06-06T11:10:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/johnson-johnson-submits-supplemental-new-drug-application-to-u-s-fda-seeking-expanded-pediatric-indication-for-hiv-1-therapy-prezcobix/ 2024-06-06T11:12:03+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/quince-therapeutics-receives-u-s-fda-fast-track-designation-for-erydex-system/ 2024-06-06T11:13:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/rinvoq-upadacitinib-now-available-for-pediatric-patients-two-years-and-older-with-polyarticular-juvenile-idiopathic-arthritis-and-psoriatic-arthritis/ 2024-06-06T11:15:17+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/abbvie-logo.jpg http://www.pharmajournalist.com/qiagen-launches-digital-pcr-assay-design-tool-for-qiacuity-expands-customization-capabilities-of-its-research-platform-geneglobe/ 2024-06-06T11:16:36+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/qiagen-image.jpg http://www.pharmajournalist.com/vyne-therapeutics-announces-dosing-of-first-subject-in-phase-2b-vitiligo-trial-of-novel-bet-inhibitor-vyn201/ 2024-06-06T11:17:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/peptide-process-development-cmc-summit-advancing-peptide-therapeutics/ 2024-06-07T12:06:24+00:00 https://pharmajournalist.com/wp-content/uploads/2024/06/Peptide-Process-Development.png http://www.pharmajournalist.com/cycle-pharmaceuticals-announces-all-cash-proposal-to-acquire-vanda-pharmaceuticals-for-8-00-per-share/ 2024-06-07T12:21:47+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/gsk-accelerates-oligonucleotide-platform-and-pipeline-medicines-with-acquisition-of-elsie-biotechnologies/ 2024-06-07T12:22:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/alzheon-raises-100-million-series-e-financing-round-to-advance-development-and-commercialization-of-oral-tablet-alz-801-valiltramiprosate-for-treatment-of-alzheimers-disease/ 2024-06-13T16:00:51+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/farxiga-approved-in-the-us-for-the-treatment-of-paediatric-type-2-diabetes/ 2024-06-13T16:02:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/flagship-pioneering-and-profound-therapeutics-announce-agreement-to-identify-novel-first-in-class-therapeutics-for-the-treatment-of-obesity-under-strategic-partnership-with-pfizer/ 2024-06-13T16:04:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/iqvia-launches-one-home-clinical-trial-technology-platform-solves-challenges-and-reduces-overload-at-sites/ 2024-06-13T16:06:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/12/IQVIA-Logo.png http://www.pharmajournalist.com/record-numbers-expected-at-cphi-pmec-china-2024-as-asian-markets-boom/ 2024-06-14T12:27:26+00:00 https://pharmajournalist.com/wp-content/uploads/2024/03/CPHI-China-2024-600_400.png http://www.pharmajournalist.com/abbvie-and-futuregen-announce-license-agreement-to-develop-next-generation-therapy-for-inflammatory-bowel-disease/ 2024-06-14T12:28:52+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/beigene-and-newbridge-pharmaceuticals-fz-llc-mutually-agree-to-conclude-brukinsa-zanubrutinib-partnership-in-the-middle-east-and-africa-mena-region/ 2024-06-14T12:31:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/subcutaneous-amivantamab-biologics-license-application-submitted-to-u-s-fda-for-patients-with-egfr-mutated-non-small-cell-lung-cancer/ 2024-06-18T12:21:38+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/charles-river-and-captain-t-cell-announce-plasmid-dna-and-viral-vector-manufacturing-alliance-for-gene-modified-cell-therapy/ 2024-06-18T12:23:17+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Charles-River.jpeg http://www.pharmajournalist.com/imfinzi-plus-chemotherapy-approved-in-the-us-for-mismatch-repair-deficient-advanced-or-recurrent-endometrial-cancer/ 2024-06-18T12:25:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/novo-nordisk-stops-the-ocedurenone-clarion-ckd-trial-and-recognises-impairment-loss/ 2024-06-27T09:32:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer/ 2024-06-27T09:34:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/lilly-collaborates-with-openai-to-discover-novel-medicines-to-treat-drug-resistant-bacteria/ 2024-06-27T09:35:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/carisma-therapeutics-granted-fda-fast-track-designation-for-ct-0525-for-the-treatment-of-her2-overexpressing-solid-tumors/ 2024-06-27T09:37:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-provides-u-s-regulatory-update-on-abbv-951-foscarbidopa-foslevodopa/ 2024-06-27T09:38:51+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/tagrisso-with-the-addition-of-chemotherapy-approved-in-japan-as-new-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer/ 2024-06-27T09:41:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/gsks-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis/ 2024-06-27T09:43:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/alnylam-reports-positive-topline-results-from-helios-b-phase-3-study-of-vutrisiran-achieving-statistical-significance-on-primary-and-all-secondary-endpoints-in-both-overall-and-monotherapy-population/ 2024-06-27T09:45:12+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/alnylam-pharmaceuticals_logo.jpg http://www.pharmajournalist.com/navidea-biopharmaceuticals-inc-announces-results-of-exploratory-analysis-completed-on-july-2-2024/ 2024-07-04T17:12:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/curevac-initiates-strategic-restructuring-to-align-resources-with-focus-on-high-value-mrna-pipeline-opportunities/ 2024-07-04T17:13:39+00:00 https://pharmajournalist.com/wp-content/uploads/2018/03/Curevac-logo.png http://www.pharmajournalist.com/boehringer-ingelheim-and-ose-immunotherapeutics-advance-clinical-development-of-first-in-class-sirpa-cancer-immunology-treatment-bi-770371/ 2024-07-04T17:15:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/pentixapharm-acquires-target-discovery-business-of-glycotope/ 2024-07-04T17:17:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/beacon-therapeutics-raises-170-million-in-series-b-funding-to-advance-development-of-ophthalmic-gene-therapies/ 2024-07-04T17:19:04+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/biogen-completes-acquisition-of-human-immunology-biosciences/ 2024-07-04T17:20:33+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/dupixent-approved-in-the-eu-as-the-first-ever-targeted-therapy-for-patients-with-copd/ 2024-07-04T17:22:47+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement/ 2024-07-04T17:24:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/calling-all-patient-advocates-join-us-to-co-create-from-the-outset-with-patients/ 2024-07-10T12:33:56+00:00 https://pharmajournalist.com/wp-content/uploads/2024/06/Pharma-Patient-USA-2024.jpg http://www.pharmajournalist.com/johnson-johnson-strengthens-pipeline-to-lead-in-atopic-dermatitis-with-acquisition-of-yellow-jersey-therapeutics/ 2024-07-11T19:34:01+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/ausperbio-receives-breakthrough-therapy-designation-for-ahb-137-in-chronic-hepatitis-b-treatment/ 2024-07-11T19:36:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/rgenta-therapeutics-announces-fda-clearance-of-ind-application-for-rgt-61159-an-oral-small-molecule-rna-modulator-designed-to-halt-disease-driver-myb-production-in-adenoid-cystic-carcinoma-acc-and/ 2024-07-11T19:37:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/evotec-and-pfizer-collaborate-to-advance-drug-discovery-in-france/ 2024-07-11T19:39:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/roche-to-reintroduce-susvimo-in-the-us-for-people-with-neovascular-age-related-macular-degeneration-namd/ 2024-07-11T19:41:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/roche-receives-ce-mark-for-its-ai-enabled-continuous-glucose-monitoring-solution-offering-critical-predictions-to-people-living-with-diabetes/ 2024-07-11T19:43:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/scirhom-secures-eur-63-million-series-a-financing-round-to-accelerate-irhom2-targeting-therapies-in-autoimmune-diseases/ 2024-07-11T19:44:36+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/moderna-and-mitsubishi-tanabe-pharma-corporation-enter-joint-agreement-to-promote-modernas-mrna-respiratory-vaccine-portfolio-in-japan-including-covid-19-vaccines/ 2024-07-11T19:46:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/catalym-announces-new-financing-of-150m-to-support-broad-phase-2b-development-program-for-visugromab/ 2024-07-18T09:14:26+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/acquisition-of-amolyt-pharma-completed/ 2024-07-18T09:16:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-designation-to-7mw3711/ 2024-07-18T09:21:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/merck-begins-commercial-production-of-first-gmp-compliant-manufacturing-line-for-cell-culture-media-in-china/ 2024-07-18T09:23:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/rona-therapeutics-raises-35-million-series-a-financing-to-advance-innovative-metabolic-sirna-pipeline-in-clinic-and-next-generation-rna-platforms/ 2024-07-19T12:31:23+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/bayer-announces-positive-topline-results-for-nubeqa-darolutamide-from-phase-iii-trial-in-men-with-metastatic-hormone-sensitive-prostate-cancer-mhspc/ 2024-07-19T12:35:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/astellas-and-graduate-school-of-medicine-faculty-of-medicine-osaka-university-enter-into-research-collaboration-to-develop-pluripotent-stem-cell-derived-cartilage-organoid-cell-therapy/ 2024-07-23T10:35:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/ac-immunes-aci-35-030-now-jnj-2056-granted-fda-fast-track-designation-for-alzheimers-disease/ 2024-07-26T10:58:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ipsen-and-day-one-enter-into-exclusive-ex-u-s-licensing-agreement-to-commercialize-tovorafenib-for-the-most-common-childhood-brain-tumor/ 2024-07-26T11:01:29+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/sandoz-launches-biosimilar-pyzchiva-ustekinumab-across-europe-to-treat-chronic-inflammatory-diseases/ 2024-07-26T11:03:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/roche-closes-acquisition-of-lumiradxs-point-of-care-technology-to-expand-access-to-diagnostic-testing-in-primary-care/ 2024-07-30T14:46:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/european-commission-approves-roches-vabysmo-for-treatment-of-retinal-vein-occlusion-rvo/ 2024-07-30T14:48:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/boehringer-ingelheim-secures-novel-immune-checkpoint-inhibitor-with-acquisition-of-nerio-therapeutics/ 2024-07-30T14:49:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/novartis-scemblix-granted-fda-priority-review-for-the-treatment-of-adults-with-newly-diagnosed-cml/ 2024-07-30T14:55:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/sk-pharmteco-and-rznomics-explore-collaboration-for-rna-based-gene-therapy-development-and-manufacturing/ 2024-08-06T12:07:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/serviers-voranigo-vorasidenib-tablets-receives-fda-approval-as-first-targeted-therapy-for-grade-2-idh-mutant-glioma/ 2024-08-07T11:45:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/ 2024-08-07T11:46:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/sangamo-therapeutics-announces-global-epigenetic-regulation-and-capsid-delivery-license-agreement-with-genentech-to-develop-novel-genomic-medicines-for-neurodegenerative-diseases/ 2024-08-07T11:48:06+00:00 https://pharmajournalist.com/wp-content/uploads/2019/02/Genentech-Building.jpeg http://www.pharmajournalist.com/gsks-jemperli-dostarlimab-plus-chemotherapy-approved-in-singapore-as-the-first-frontline-immuno-oncology-treatment-for-dmmr-msi-h-primary-advanced-or-recurrent-endometrial-cancer/ 2024-08-07T11:52:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/fda-approves-yorvipath-palopegteriparatide-as-the-first-and-only-treatment-for-hypoparathyroidism-in-adults/ 2024-08-13T08:43:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/pfizer-announces-top-line-results-of-abrysvo-for-rsv-in-immunocompromised-adults/ 2024-08-13T08:44:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-fda/ 2024-08-15T17:02:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/incyte-and-syndax-announce-fda-approval-of-niktimvo-axatilimab-csfr-for-the-treatment-of-chronic-graft-versus-host-disease-gvhd/ 2024-08-15T17:04:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/replimune-announces-first-patient-dosed-in-ignyte-3-clinical-trial-in-advanced-melanoma/ 2024-08-15T17:06:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.png http://www.pharmajournalist.com/enhertu-approved-in-china-for-patients-with-previously-treated-her2-positive-advanced-or-metastatic-gastric-cancer/ 2024-08-15T17:07:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/lilly-opens-state-of-the-art-research-and-development-center-in-the-boston-seaport/ 2024-08-15T17:08:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/pantherx-rare-partnering-with-gilead-sciences-inc-for-the-distribution-of-livdelzi/ 2024-08-19T23:41:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/enhertu-granted-breakthrough-therapy-designation-in-u-s-for-certain-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer/ 2024-08-19T23:42:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/achieving-clinical-success-with-safe-efficacious-tgf-b-therapies/ 2024-08-23T12:31:57+00:00 https://pharmajournalist.com/wp-content/uploads/2024/07/TGF-B-Targeted-Drug-Development-Summit.jpg http://www.pharmajournalist.com/achieving-affordable-individualized-vaccines-for-cancer-patients-faster/ 2024-08-23T12:33:48+00:00 https://pharmajournalist.com/wp-content/uploads/2024/08/47392-Pharma-J-Banner-4.png http://www.pharmajournalist.com/ec-approves-astellas-padcevtm-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-urothelial-cancer/ 2024-08-28T11:10:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/lilly-releases-zepbound-tirzepatide-single-dose-vials-expanding-supply-and-access-for-adults-living-with-obesity/ 2024-08-28T11:11:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/pfizer-launches-pfizerforall-a-digital-platform-that-helps-simplify-access-to-healthcare/ 2024-08-28T11:13:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/roches-piasky-approved-in-the-eu-as-the-first-monthly-subcutaneous-treatment-for-people-with-pnh/ 2024-08-28T11:14:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/beigenes-bgb-16673-receives-fda-fast-track-designation-for-cll-sll/ 2024-08-28T11:16:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/ucb-to-accelerate-innovation-and-strategic-partnerships-divesting-mature-product-portfolio-in-china/ 2024-08-28T11:18:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/aptose-receives-10-million-through-a-facility-agreement-with-hanmi-negotiating-future-collaboration-agreement-with-hanmi-to-jointly-develop-tuspetinib/ 2024-09-02T13:51:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/european-commission-approves-expanded-age-indication-for-gsks-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/ 2024-09-02T13:53:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/primrose-bio-and-explorna-therapeutics-announce-strategic-partnership-to-advance-mrna-medicines/ 2024-09-04T12:20:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/innovent-receives-fast-track-designation-from-the-u-s-fda-for-ibi363-pd-1-il-2%ce%b1-bispecific-antibody-fusion-protein-as-monotherapy-for-advanced-melanoma/ 2024-09-04T12:21:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/regenxbio-announces-positive-data-from-pivotal-dose-level-of-rgx-121-demonstrating-long-term-systemic-effect/ 2024-09-04T12:22:59+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/REGENXBIO-logo.png http://www.pharmajournalist.com/european-commission-approves-mercks-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-first-line-treatment-of-unresectable-or-metastatic-urothelial-carcinoma-in-adults/ 2024-09-04T12:24:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/abdera-therapeutics-announces-fda-orphan-drug-designation-for-abd-147-for-the-treatment-of-neuroendocrine-carcinoma/ 2024-09-06T12:00:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/nimmune-biopharma-announces-rd-collaboration-with-biotherapeutics-inc-to-advance-the-next-wave-of-inflammation-and-immunology-precision-medicines/ 2024-09-06T12:02:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/amneal-and-shilpa-announce-fda-approval-of-boruzu-the-first-ready-to-use-version-of-bortezomib-for-subcutaneous-administration/ 2024-09-06T12:03:47+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/evotec-and-x-chem-collaborate-to-accelerate-early-stage-drug-discovery/ 2024-09-06T12:06:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/global-leaders-in-cell-therapy-for-autoimmune-diseases-converge-at-the-2nd-cell-therapy-for-autoimmune-disease-summit/ 2024-09-11T07:40:19+00:00 https://pharmajournalist.com/wp-content/uploads/2024/09/Cell-Autoimmune-Image-2.jpg https://pharmajournalist.com/wp-content/uploads/2024/09/Cell-Autoimmune-Image-1.png https://pharmajournalist.com/wp-content/uploads/2024/09/Cell-Autoimmune-Image-2.jpg http://www.pharmajournalist.com/candid-therapeutics-debuts-with-370m-capital-raise-to-clinically-evaluate-potentially-transformative-autoimmune-therapies/ 2024-09-11T07:43:07+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/vir-biotechnology-announces-closing-of-exclusive-worldwide-license-agreement-with-sanofi-for-multiple-potential-best-in-class-clinical-stage-t-cell-engagers/ 2024-09-11T07:44:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/02/VIR-Logo.jpg http://www.pharmajournalist.com/modernas-canadian-manufacturing-facility-receives-drug-establishment-license-from-health-canada/ 2024-09-11T07:45:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ 2024-09-11T07:47:16+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/gilead-and-genesis-therapeutics-announce-strategic-collaboration-to-discover-and-develop-novel-therapies/ 2024-09-11T07:48:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/sophia-genetics-and-astrazeneca-collaborate-to-further-expand-global-access-to-liquid-biopsy-testing/ 2024-09-11T07:50:55+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/cell-therapy-analytical-and-quality-control-experts-to-gather-in-boston-this-december-for-the-6th-cell-therapy-analytical-development-summit/ 2024-09-19T06:28:46+00:00 https://pharmajournalist.com/wp-content/uploads/2024/08/6th-Cell-Therapy-Analytical-Development-Summit.jpg http://www.pharmajournalist.com/fda-approves-novartis-kisqali-to-reduce-risk-of-recurrence-in-people-with-hr-her2-early-breast-cancer/ 2024-09-19T06:31:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/blenrep-belantamab-mafodotin-combinations-in-relapsed-refractory-multiple-myeloma-accepted-for-regulatory-review-in-japan/ 2024-09-19T06:32:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/orbis-medicines-and-vivtex-form-research-exclusive-licensing-collaboration-to-support-orbis-development-of-next-generation-orally-dosable-ncycles/ 2024-09-19T06:33:45+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/beigene-receives-israeli-ministry-of-health-approval-for-tevimbra-for-the-treatment-of-oesophageal-squamous-cell-carcinoma-oscc-after-prior-chemotherapy/ 2024-09-19T06:35:03+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/nura-bio-closes-series-a-financing-with-68-million-in-new-funds-bringing-total-raised-to-140-million/ 2024-09-19T06:36:20+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/valneva-submits-label-extension-applications-for-its-chikungunya-vaccine-ixchiq-to-ema-and-health-canada/ 2024-09-19T06:38:33+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/zentalis-pharmaceuticals-announces-fda-has-lifted-partial-clinical-hold-on-azenosertib-studies/ 2024-09-19T06:39:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/maxcyte-signs-strategic-platform-license-with-kamau-therapeutics-to-accelerate-the-development-of-cell-therapies-for-genetic-diseases/ 2024-09-19T06:41:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sanofi-shipping-beyfortus-in-us-to-help-protect-babies-against-rsv-disease-new-manufacturing-line-approved-by-fda/ 2024-09-19T06:43:00+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/fda-approves-mercks-keytruda-pembrolizumab-plus-pemetrexed-and-platinum-chemotherapy-as-first-line-treatment-for-adult-patients-with-unresectable-advanced-or-metastatic-malignant-pleural-me/ 2024-09-19T06:45:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/papillon-therapeutics-secures-orphan-drug-designation-from-fda-for-ppl-001-in-friedreichs-ataxia-treatment/ 2024-09-19T06:48:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/minervax-and-wacker-biotech-join-forces-for-manufacturing-of-prophylactic-vaccine-against-group-b-streptococcus/ 2024-09-19T06:50:36+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-declines-to-approve-vandas-marketing-application-for-tradipitant-in-gastroparesis/ 2024-09-20T11:41:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis/ 2024-09-20T11:43:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/tempus-expands-partnership-with-takeda-to-enhance-oncology-research-using-multimodal-real-world-data-and-biological-models/ 2024-09-27T12:20:53+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/phare-bio-secures-up-to-27-million-from-arpa-h-to-propel-ai-driven-drug-discovery-and-innovate-new-antibiotics/ 2024-09-27T12:22:52+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/boehringer-ingelheim-partners-with-ncd-alliance-to-target-non-communicable-diseases-in-underserved-communities/ 2024-09-27T12:24:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/tagrisso-approved-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer/ 2024-09-27T12:26:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/askbio-to-collaborate-with-belief-biomed-to-explore-the-potential-of-new-gene-therapies/ 2024-09-27T12:28:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worldwide-markets/ 2024-09-27T12:29:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/bayer-co-lab-shanghai-opens-as-part-of-global-expansion-of-life-science-incubator-network/ 2024-09-27T12:31:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/lillys-kisunla-donanemab-azbt-approved-in-japan-for-the-treatment-of-early-symptomatic-alzheimers-disease/ 2024-09-27T12:33:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/acumen-pharmaceuticals-extends-collaboration-with-lonza-to-add-drug-product-manufacturing-of-sabirnetug-for-early-alzheimers-disease/ 2024-09-27T12:35:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/lonza.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-expands-oral-solid-dose-development-and-manufacturing-capabilities-across-north-america/ 2024-09-27T12:37:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/recordati-strengthens-rare-diseases-portfolio-with-acquisition-of-global-rights-to-enjaymo/ 2024-10-04T13:04:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-approves-neoadjuvant-opdivo-and-chemotherapy-for-resectable-non-small-cell-lung-cancer-treatment-pathway/ 2024-10-04T13:06:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/resilience-secures-funding-to-expand-domestic-manufacturing-for-critical-pharmaceutical-ingredients/ 2024-10-04T13:08:19+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/resolution-therapeutics-announces-63-5-million-series-b-financing-and-chair-appointment/ 2024-10-04T13:10:17+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/teva-and-mabxience-strengthen-strategic-alliance-with-new-oncology-biosimilar-candidate-addition/ 2024-10-04T13:12:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/immunoprecise-subsidiary-signs-material-transfer-agreement-with-biotheus/ 2024-10-04T13:14:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/gilead-partners-with-six-generic-manufacturers-for-royalty-free-licensing-to-boost-lenacapavir-access-for-hiv-prevention-in-resource-limited-countries/ 2024-10-04T13:16:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/abl-bio-launches-clinical-collaboration-to-assess-abl103-with-keytruda-in-solid-tumor-patients/ 2024-10-04T13:19:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/south-koreas-sk-bioscience-completes-acquisition-of-germanys-cdmo-idt-biologika/ 2024-10-04T13:20:51+00:00 https://pharmajournalist.com/wp-content/uploads/2023/11/SK-bioscience.png http://www.pharmajournalist.com/arcus-biosciences-announces-clinical-trial-collaboration-agreement-to-evaluate-casdatifan-in-combination-with-volrustomig-in-renal-cell-carcinoma/ 2024-10-04T13:22:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/charles-river-and-lundbeck-collaborate-to-harness-ai-powered-logica-for-novel-neurological-drug-discovery/ 2024-10-04T13:24:02+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Charles-River.jpeg http://www.pharmajournalist.com/geneditbio-secures-strategic-investment-from-gobi-partners-gba-to-accelerate-breakthrough-genome-editing-technologies/ 2024-10-04T13:25:18+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/bayer-and-moma-therapeutics-enter-collaboration-and-license-agreement-in-oncology/ 2024-10-08T14:30:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/boehringer-receives-fda-breakthrough-therapy-designation-and-initiates-two-phase-iii-trials-in-mash-for-survodutide/ 2024-10-08T14:32:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/innovent-and-ask-pharm-announce-strategic-collaboration-for-limertinib-a-third-generation-egfr-tki-for-the-treatment-of-lung-cancer/ 2024-10-08T14:34:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/biogen-secures-fda-breakthrough-therapy-designation-for-felzartamab-to-combat-antibody-mediated-rejection-in-kidney-transplants/ 2024-10-11T12:02:18+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/insitro-and-lilly-enter-strategic-agreements-to-advance-novel-treatments-for-metabolic-diseases/ 2024-10-11T12:05:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/arda-therapeutics-secures-43m-series-a-financing-to-advance-targeted-cell-depletion-therapies/ 2024-10-11T12:07:23+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-circle-pharma-announce-new-research-collaboration-to-develop-a-novel-precision-cancer-treatment/ 2024-10-11T12:08:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/fda-approves-roches-itovebi-a-targeted-treatment-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation/ 2024-10-11T12:10:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/teva-prolia-denosumab-biosimilar-candidate-is-accepted-for-review-by-fda-and-eu-ema/ 2024-10-11T12:12:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/viatris-announces-exclusive-licensing-agreement-with-lexicon-pharmaceuticals-for-sotagliflozin-in-all-markets-outside-of-the-u-s-and-europe/ 2024-10-17T22:38:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/firefly-neuroscience-collaborates-with-bright-minds-biosciences-to-analyze-the-data-from-its-positive-phase-1-study-using-its-artificial-intelligence-fda-cleared-bna-technology/ 2024-10-17T22:39:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sellas-announces-fda-rare-pediatric-disease-designation-rpdd-granted-to-galinpepimut-s-gps-for-the-treatment-of-pediatric-acute-myeloid-leukemia/ 2024-10-17T22:40:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/exelixis-and-merck-partner-to-advance-zanzalintinib-trials-with-keytruda-in-head-and-neck-cancer-and-welireg-in-renal-cell-carcinoma/ 2024-10-17T22:43:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/ucb-secures-fda-approval-for-320-mg-single-injection-device-of-bimzelx-bimekizumab-bkzx/ 2024-10-17T22:45:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/enhertu-gains-approval-in-china-as-first-her2-directed-therapy-for-her2-mutant-metastatic-non-small-cell-lung-cancer/ 2024-10-17T22:46:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/sanofi-and-orano-join-forces-to-develop-next-generation-radioligand-medicines/ 2024-10-17T22:50:56+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/atomvie-global-radiopharma-and-radiopharm-theranostics-join-forces-to-develop-177lu-betabart-radioantibody-for-solid-tumor-treatment/ 2024-10-17T22:53:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/be-bio-announces-82-million-financing-and-transition-to-clinical-stage-company/ 2024-10-24T11:38:09+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/lillys-kisunla-gains-marketing-authorization-in-great-britain-for-alzheimers-treatment-in-select-adult-patients/ 2024-10-24T11:38:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/european-commission-approves-darzalex-daratumumab-sc-quadruplet-regimen-for-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma/ 2024-10-24T11:48:30+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/fda-approves-pfizers-rsv-vaccine-abrysvo-for-adults-aged-18-to-59-at-increased-risk-for-disease/ 2024-10-24T11:49:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/ocuphire-pharma-announces-acquisition-of-opus-genetics/ 2024-10-24T11:51:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/treefrog-therapeutics-enters-into-pioneering-research-collaboration-in-immuno-oncology-with-the-university-of-pittsburgh/ 2024-10-24T11:53:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/alvotech-and-teva-receive-fda-approval-for-expanded-selarsdi-ustekinumab-aekn-presentation-aligning-indications-with-stelara-ustekinumab/ 2024-10-24T11:55:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/hottest-gene-editing-events-causing-waves-in-2024/ 2024-10-29T11:34:48+00:00 https://pharmajournalist.com/wp-content/uploads/2024/10/Pharma-J-4-Graphic.png https://pharmajournalist.com/wp-content/uploads/2024/10/Pharma-J-4-Graphic.png http://www.pharmajournalist.com/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis/ 2024-10-29T11:47:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/iterum-therapeutics-receives-fda-approval-of-orlynvah-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections/ 2024-10-29T11:49:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-to-acquire-aliada-therapeutics-strengthening-focus-in-alzheimers-disease-and-neuroscience-pipeline/ 2024-10-29T11:50:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/abbvie.jpg http://www.pharmajournalist.com/astellas-provides-update-on-marketing-authorization-application-for-avacincaptad-pegol-acp-in-the-european-union/ 2024-10-29T11:51:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/join-the-gene-editing-revolution-this-december/ 2024-10-30T13:16:57+00:00 https://pharmajournalist.com/wp-content/uploads/2024/09/48775-Pharma-J-Banner.png http://www.pharmajournalist.com/shaping-the-future-of-therapeutic-gene-editing/ 2024-10-30T13:17:26+00:00 https://pharmajournalist.com/wp-content/uploads/2024/09/48775-Pharma-J-Banner.png http://www.pharmajournalist.com/a-timeline-of-gene-editing-landmarks/ 2024-10-30T13:18:17+00:00 https://pharmajournalist.com/wp-content/uploads/2024/10/Pharma-J-3-Graphic.png https://pharmajournalist.com/wp-content/uploads/2024/10/Pharma-J-3-Graphic.png http://www.pharmajournalist.com/biogen-and-neomorph-announce-multi-target-research-collaboration-to-discover-and-develop-molecular-glue-degraders-for-alzheimers-rare-and-immunological-diseases/ 2024-10-31T11:38:20+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/novartis-scemblix-fda-approved-in-newly-diagnosed-cml-offering-superior-efficacy-and-favorable-safety-and-tolerability-profile/ 2024-10-31T11:40:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/gsk-enters-agreement-to-acquire-cmg1a46-from-chimagen-biosciences-to-expand-immunology-pipeline/ 2024-10-31T11:41:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/an-interview-with-jeffrey-cehelsky-intellia-therapeutics/ 2024-11-01T12:50:23+00:00 https://pharmajournalist.com/wp-content/uploads/2024/09/48775-Pharma-J-Banner.png http://www.pharmajournalist.com/final-week-to-save-350-accelerate-your-gene-editing-program/ 2024-11-06T10:27:52+00:00 https://pharmajournalist.com/wp-content/uploads/2024/11/47290-4.png https://pharmajournalist.com/wp-content/uploads/2024/11/47290-4.png http://www.pharmajournalist.com/dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young-children-with-eosinophilic-esophagitis/ 2024-11-07T14:55:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/nxera-pharma-and-antiverse-enter-collaboration-to-design-novel-gpcr-targeted-antibody-therapeutics-using-generative-ai/ 2024-11-07T14:57:14+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/expanded-age-indication-for-gsks-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-approved-in-canada-for-adults-aged-50-59-at-increased-risk/ 2024-11-07T14:58:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/nektar-announces-definitive-agreement-with-ampersand-capital-partners-to-sell-its-commercial-pegylation-reagent-manufacturing-business-in-alabama/ 2024-11-07T15:02:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/08/Nektar-Therapeutics-Logo.jpg http://www.pharmajournalist.com/leads-biolabs-secures-orphan-drug-designation-from-us-fda-for-lbl-034-a-novel-anti-gprc5d-cd3-bispecific-antibody-targeting-multiple-myeloma/ 2024-11-07T15:04:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/inocras-and-summit-pharmaceuticals-international-corporation-announce-collaboration-aim-to-transform-clinical-genomics-in-japan/ 2024-11-07T15:06:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ascendis-pharma-and-novo-nordisk-sign-collaboration-for-development-and-commercialization-of-transcon-technology-based-products-in-metabolic-and-cardiovascular-diseases/ 2024-11-07T15:07:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/clearside-biomedical-partner-arctic-vision-executes-commercial-collaboration-agreement-with-santen-pharmaceutical-co-ltd-for-arvn001-suprachoroidal-space-injection-therapy-for-the-treatment-of-uveit/ 2024-11-08T10:07:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/aditum-bio-and-leads-biolabs-announce-the-formation-of-oblenio-bio-to-develop-a-tri-specific-t-cell-engager-for-autoimmune-disorders/ 2024-11-08T10:08:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/celebrating-more-than-a-decade-of-excellence-at-the-world-adc-awards-winners-announcement/ 2024-11-08T10:38:27+00:00 https://pharmajournalist.com/wp-content/uploads/2024/11/11th-World-ADC-Awards.png http://www.pharmajournalist.com/biontech-to-acquire-biotheus-to-boost-oncology-strategy/ 2024-11-14T11:43:57+00:00 https://pharmajournalist.com/wp-content/uploads/2018/08/BioNTech-AG.jpg http://www.pharmajournalist.com/ojjaara-momelotinib-approved-in-canada-for-the-treatment-of-myelofibrosis-in-adults-who-have-moderate-to-severe-anemia/ 2024-11-14T13:44:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/ontada-collaborates-with-datavant-to-enable-faster-access-to-market-leading-oncology-insights/ 2024-11-14T13:45:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-removes-clinical-hold-on-novavaxs-covid-19-influenza-combination-and-stand-alone-influenza-phase-3-trial/ 2024-11-14T13:46:55+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/nippon-shinyaku-and-atsena-therapeutics-enter-into-an-exclusive-strategic-collaboration-for-atsn-101-in-the-u-s-and-japan/ 2024-11-14T13:48:44+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/datopotamab-deruxtecan-bla-submitted-for-accelerated-approval-in-the-u-s-for-advanced-egfr-mutated-non-small-cell-lung-cancer/ 2024-11-14T13:50:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/apollo-therapeutics-signs-exclusive-ex-china-license-from-sunshine-lake-pharma-for-clinical-stage-fgf21-glp-1-dual-receptor-agonist-a-therapeutic-with-major-commercial-potential-in-multiple-indicat/ 2024-11-14T13:53:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/qiagen-collaborates-with-mcgill-university-to-advance-microbiome-research/ 2024-11-14T13:54:12+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/qiagen-image.jpg http://www.pharmajournalist.com/5th-genome-editing-therapeutics-summit-is-only-3-weeks-away/ 2024-11-14T14:22:06+00:00 https://pharmajournalist.com/wp-content/uploads/2024/11/47290-4.png http://www.pharmajournalist.com/enveda-closes-130m-series-c-funding-to-deliver-multiple-clinical-readouts-from-a-pipeline-of-10-development-candidates/ 2024-11-22T12:20:45+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda-approval-of-exenatide-its-first-generic-injectable-glp-1-agonist/ 2024-11-22T12:26:04+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/samsung-biologics-signs-manufacturing-deal-with-european-pharmaceutical-company/ 2024-11-22T12:27:58+00:00 https://pharmajournalist.com/wp-content/uploads/2019/08/Samsung-BioLogics-and-UCB.jpg http://www.pharmajournalist.com/zai-lab-and-pfizer-announce-strategic-collaboration-on-the-novel-antibacterial-drug-xacduro-sulbactam-durlobactam/ 2024-11-22T12:30:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/genprex-signs-exclusive-license-to-additional-gene-therapy-technologies-with-the-university-of-michigan-for-the-treatment-of-lung-cancer/ 2024-11-22T12:31:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/alloy-therapeutics-signs-collaboration-and-license-agreement-with-takeda-to-develop-cell-therapy-platform/ 2024-11-22T12:33:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/kura-oncology-and-kyowa-kirin-announce-global-strategic-collaboration-to-develop-and-commercialize-ziftomenib-in-acute-leukemias/ 2024-11-22T12:35:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/european-commission-approves-pfizers-hympavzi-marstacimab-for-the-treatment-of-adults-and-adolescents-with-severe-hemophilia-a-or-b-without-inhibitors/ 2024-11-22T12:40:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/sarepta-therapeutics-announces-global-licensing-and-collaboration-agreement-with-arrowhead-pharmaceuticals-for-multiple-clinical-and-preclinical-sirna-programs/ 2024-11-27T13:24:37+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Sarepta-Therapeutics.jpg http://www.pharmajournalist.com/eton-pharmaceuticals-announces-acquisition-of-u-s-rights-to-amglidia-glyburide-oral-suspension/ 2024-11-27T13:26:00+00:00 https://pharmajournalist.com/wp-content/uploads/2019/06/Eton-Pharma-Logo.png http://www.pharmajournalist.com/roche-enters-into-a-definitive-agreement-to-acquire-poseida-therapeutics-including-cell-therapy-candidates-and-related-platform-technologies/ 2024-11-27T13:27:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/acadia-pharmaceuticals-announces-exclusive-license-agreement-with-saniona-for-san711/ 2024-11-27T13:29:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/shorla-oncology-announces-fda-approval-of-imkeldi-imatinib-oral-solution-an-oral-liquid-for-the-treatment-of-certain-forms-of-leukemia-and-other-cancers/ 2024-11-27T13:31:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/arexvy-approval-expanded-to-adults-aged-50-59-at-increased-risk-of-severe-rsv-disease-in-japan/ 2024-11-27T13:33:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/alnylam-announces-u-s-food-and-drug-administration-acceptance-of-supplemental-new-drug-application-for-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-cardiomyopathy/ 2024-11-27T13:36:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/valneva-submits-label-extension-application-for-its-chikungunya-vaccine-ixchiq-to-the-u-s-fda/ 2024-11-27T13:39:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/adragos-pharma-acquires-baccinex-a-leading-swiss-sterile-fill-finish-expert/ 2024-11-27T13:43:09+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/lillys-zepbound-tirzepatide-superior-to-wegovy-semaglutide-in-head-to-head-trial-showing-an-average-weight-loss-of-20-2-vs-13-7/ 2024-12-04T19:17:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/ipsen-and-biomunex-announce-exclusive-global-licensing-agreement-for-first-in-class-mait-cell-engager-in-immuno-oncology/ 2024-12-04T19:19:30+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/takeda-strengthens-oncology-pipeline-with-elritercept-through-licensing-agreement-with-keros-therapeutics/ 2024-12-04T19:20:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/novartis-bolsters-neuroscience-pipeline-with-in-licensing-of-ptc518-for-huntingtons-disease/ 2024-12-04T19:23:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/maze-therapeutics-announces-oversubscribed-115-million-financing-to-support-advancement-of-clinical-stage-programs-and-future-pipeline/ 2024-12-04T19:25:07+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/johnson-johnson-seeks-u-s-fda-approval-for-first-pediatric-indications-for-tremfya-guselkumab/ 2024-12-04T19:26:48+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/two-combination-vaccine-candidates-for-prevention-of-influenza-and-covid-19-granted-fast-track-designation-in-the-us/ 2024-12-12T12:25:52+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/fda-accepts-gsks-submission-for-the-use-of-nucala-mepolizumab-in-copd/ 2024-12-12T12:28:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/datopotamab-deruxtecan-granted-breakthrough-therapy-designation-in-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer/ 2024-12-12T12:30:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/pilatus-biosciences-receives-fda-orphan-drug-designation-for-plt012-in-liver-cancer/ 2024-12-12T12:33:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/santhera-gets-nmpa-approval-for-agamree-vamorolone-in-duchenne-muscular-dystrophy/ 2024-12-12T12:36:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/nona-biosciences-and-kodiak-sciences-partner-on-next-gen-ophthalmic-antibody-therapies/ 2024-12-12T12:38:24+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-grants-breakthrough-therapy-designation-to-seres-therapeutics-ser-155-for-bloodstream-infections/ 2024-12-12T12:40:26+00:00 https://pharmajournalist.com/wp-content/uploads/2021/07/Seres-Therapeutics.jpg http://www.pharmajournalist.com/gsks-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps/ 2025-01-06T19:06:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/european-commission-ec-extends-the-approval-of-evkeeza-evinacumab-to-children-as-young-as-6-months-old-with-homozygous-familial-hypercholesterolemia-hofh/ 2025-01-06T19:08:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Ultragenyxlogo.gif http://www.pharmajournalist.com/chinas-nmpa-approves-vyloy-zolbetuximab-for-first-line-treatment-of-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma/ 2025-01-06T19:18:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/brii-bio-announces-signing-of-asset-purchase-agreements-acquiring-brii-179-ip-rights-and-completed-patient-enrollment-for-enrich-study/ 2025-01-06T19:19:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/lpoxy-therapeutics-inc-acquires-key-assets-from-xeno-biosciences-inc-to-advance-c-difficile-prevention-therapy/ 2025-01-06T19:23:43+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gsks-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma/ 2025-01-08T11:00:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/candid-therapeutics-enters-into-agreement-with-wuxi-biologics-on-trispecific-t-cell-engager/ 2025-01-08T11:02:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sentynl-announces-fda-acceptance-and-priority-review-of-cutx-101-for-menkes-disease/ 2025-01-08T11:04:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/tempest-receives-orphan-drug-designation-for-amezalpat-in-hcc-treatment/ 2025-01-08T11:06:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/variant-bio-partners-with-novo-nordisk-to-discover-metabolic-disease-targets/ 2025-01-08T11:10:10+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/amgens-imdylltra-granted-conditional-approval-for-small-cell-lung-cancer-in-uk/ 2025-01-08T11:13:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/fda-granted-priority-review-to-dizals-sunvozertinib-new-drug-application/ 2025-01-08T11:14:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/solid-biosciences-receives-fda-ind-clearance-for-dual-route-gene-therapy-in-friedreichs-ataxia/ 2025-01-08T11:16:18+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/solid-biosciences.jpg http://www.pharmajournalist.com/be-bio-announces-closing-of-92m-series-c-financing-and-completes-transition-to-a-multi-program-clinical-stage-company/ 2025-01-16T12:18:20+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/regenxbio-and-nippon-shinyaku-form-exclusive-partnership-to-develop-rgx-121-and-rgx-111-for-mps-diseases/ 2025-01-16T12:20:53+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/abbvie-and-simcere-zaiming-partner-to-develop-trispecific-antibody-for-multiple-myeloma/ 2025-01-16T12:21:57+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/fda-approves-lillys-omvoh-for-crohns-disease-expanding-ibd-treatment-options/ 2025-01-16T12:24:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/acadia-pharmaceuticals-submits-ema-application-for-trofinetide-in-rett-syndrome/ 2025-01-16T12:28:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/umoja-biopharma-secures-100m-in-oversubscribed-series-c-to-advance-car-t-pipeline/ 2025-01-16T12:29:34+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/daiichi-sankyo-acquires-ip-rights-for-anti-ta-muc1-antibody-ds-3939-from-glycotope/ 2025-01-16T12:31:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/fda-accepts-leqembi-bla-for-subcutaneous-dosing-in-early-alzheimers-treatment/ 2025-01-16T12:33:49+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/EISAI.jpg http://www.pharmajournalist.com/axcynsis-receives-fda-clearance-for-ind-of-at03-65-cldn6-targeting-adc/ 2025-01-16T12:36:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-spravato-esketamine-as-first-and-only-monotherapy-for-treatment-resistant-depression-in-adults/ 2025-01-23T12:58:33+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/glox-therapeutics-secures-share-of-3m-funding-to-combat-antibiotic-resistance-in-cystic-fibrosis/ 2025-01-23T13:06:55+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/cellipont-bioservices-to-manufacture-master-cell-bank-for-secretome-therapeutics-lead-asset-stm-01/ 2025-01-23T13:09:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/catalent-announces-collaboration-with-galapagos-to-further-expand-galapagos-decentralized-car-t-manufacturing-network-in-the-u-s/ 2025-01-23T13:10:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Catalent-logo.png http://www.pharmajournalist.com/zai-labs-zl-1310-earns-fda-orphan-drug-designation-for-small-cell-lung-cancer-treatment/ 2025-01-23T13:13:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/dyne-therapeutics-dyne-101-granted-fda-fast-track-designation-for-myotonic-dystrophy-type-1/ 2025-01-23T13:15:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/junshi-biosciences-announces-commercialization-partnership-with-leo-pharma-for-toripalimab-in-europe/ 2025-01-23T13:16:41+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pfizers-braftovi-combination-regimen-demonstrates-improved-response-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer/ 2025-01-27T20:25:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-mercks-welireg-for-advanced-pheochromocytoma-and-paraganglioma/ 2025-01-27T20:27:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/fda-approves-leqembi-iv-maintenance-dosing-for-early-alzheimers-disease/ 2025-01-27T20:30:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/tevogen-bio-expands-ai-partnership-with-microsoft-to-advance-predictcell-on-azure/ 2025-01-27T20:33:18+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/lupin-receives-u-s-fda-approval-for-sacubitril-and-valsartan-tablets/ 2025-01-27T20:34:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/lupin-pharma.jpg http://www.pharmajournalist.com/abbvie-and-neomorph-partner-to-develop-molecular-glue-degraders-for-oncology-and-immunology/ 2025-01-27T20:36:29+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/astrazeneca-to-invest-c820m-in-canada-to-expand-global-hub-and-clinical-delivery/ 2025-01-27T20:38:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/imfinzi-recommended-for-eu-approval-as-first-immunotherapy-for-limited-stage-small-cell-lung-cancer/ 2025-02-04T08:46:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/pfizers-braftovi-combo-boosts-survival-in-phase-3-breakwater-trial/ 2025-02-04T08:48:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/sarclisa-approved-in-china-as-first-anti-cd38-treatment-for-newly-diagnosed-multiple-myeloma/ 2025-02-04T08:50:02+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/european-commission-approves-viivs-vocabria-rekambys-for-hiv-treatment-in-adolescents/ 2025-02-04T08:52:01+00:00 https://pharmajournalist.com/wp-content/uploads/2020/07/ViiV-Healthcare.png http://www.pharmajournalist.com/vertex-announces-fda-approval-of-first-in-class-pain-treatment-journavx-for-adults/ 2025-02-04T08:53:47+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/purple-biotech-partners-with-mount-sinai-for-captn-3-tri-specific-antibody-research/ 2025-02-04T08:55:50+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/kazia-therapeutics-launches-groundbreaking-trial-of-paxalisib-and-immunotherapy-for-advanced-breast-cancer/ 2025-02-04T08:59:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/orion-and-invenra-partner-to-develop-bispecific-antibody-cancer-therapies/ 2025-02-04T09:00:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/immunitybio-partners-with-beigene-on-phase-3-trial-for-anktiva-and-pd-1-combo-in-nsclc/ 2025-02-04T09:03:20+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/ImmunityBio-Logo.png http://www.pharmajournalist.com/supernus-receives-fda-approval-for-onapgo-apomorphine-hydrochloride-in-parkinsons-disease-treatment/ 2025-02-06T12:52:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/valneva-gets-uk-marketing-authorization-for-worlds-first-chikungunya-vaccine-ixchiq/ 2025-02-06T12:55:54+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/astellas-submits-nda-for-conditional-approval-of-avacincaptad-pegol-for-geographic-atrophy-in-japan/ 2025-02-06T12:58:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/harbour-biomed-gets-nmpa-ind-clearance-for-hbm9378-skb378-in-copd-treatment/ 2025-02-06T13:00:41+00:00 https://pharmajournalist.com/wp-content/uploads/2019/06/Harbour-BioMed-Logo.jpg http://www.pharmajournalist.com/shionogi-and-guardian-angels-launch-first-ever-human-drug-study-for-jordans-syndrome/ 2025-02-06T13:06:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/debra-research-and-leo-pharma-form-partnership-to-advance-rare-skin-disease-treatments/ 2025-02-06T13:09:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/leo-pharma.jpg http://www.pharmajournalist.com/auron-therapeutics-gains-fda-clearance-for-autx-703-and-completes-series-b-financing/ 2025-02-06T13:10:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/biontech-completes-acquisition-of-biotheus/ 2025-02-06T13:12:26+00:00 https://pharmajournalist.com/wp-content/uploads/2018/08/BioNTech-AG.jpg http://www.pharmajournalist.com/novartis-strengthens-cardiovascular-pipeline-with-925-million-anthos-therapeutics-acquisition/ 2025-02-11T12:36:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/boehringers-nerandomilast-hits-primary-endpoint-in-phase-iii-fibroneer-ild-for-pulmonary-fibrosis/ 2025-02-11T12:38:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/bio-thera-solutions-signs-exclusive-license-deal-with-intas-for-bat2506-biosimilar-in-the-u-s/ 2025-02-11T12:41:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-approves-emblaveo-for-treatment-of-complicated-intra-abdominal-infections/ 2025-02-11T12:43:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/abbvie.jpg http://www.pharmajournalist.com/alumis-and-acelyrin-to-merge-forming-biopharma-leader-in-immune-mediated-diseases/ 2025-02-11T12:45:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/henlius-and-dr-reddys-partner-on-hlx15-biosimilar-expansion-in-europe-and-u-s/ 2025-02-11T12:47:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/biodexa-secures-fda-fast-track-designation-for-erapa-in-familial-adenomatous-polyposis/ 2025-02-11T12:49:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/immuneering-signs-clinical-supply-deal-with-regeneron-to-test-imm-1-104-with-libtayo/ 2025-02-11T12:51:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/nemluvio-approved-in-eu-for-atopic-dermatitis-and-prurigo-nodularis/ 2025-02-14T12:23:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/newleos-therapeutics-raises-93-5m-in-oversubscribed-series-a-to-advance-neuropsychiatric-disorder-treatments/ 2025-02-14T12:24:50+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/abbvie-and-xilio-therapeutics-partner-to-develop-tumor-activated-immunotherapies/ 2025-02-14T12:26:21+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/lundbecks-amlenetug-for-msa-receives-fda-fast-track-designation/ 2025-02-14T12:28:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/lundbeck-logo.jpg http://www.pharmajournalist.com/health-canada-approves-mercks-keytruda-for-resectable-nsclc-with-chemotherapy/ 2025-02-14T12:30:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/qiagen-expands-bioinformatics-leadership-with-new-data-center-in-australia-apac/ 2025-02-14T12:32:02+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/qiagen-image.jpg http://www.pharmajournalist.com/maxcyte-signs-platform-license-with-tg-therapeutics-for-autoimmune-cell-therapies/ 2025-02-14T12:33:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/biogen-and-stoke-therapeutics-partner-to-develop-zorevunersen-for-dravet-syndrome-treatment/ 2025-02-19T12:04:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/fda-accepts-gileads-nda-for-twice-yearly-lenacapavir-for-hiv-prevention/ 2025-02-19T12:05:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/fda-accepts-dupixent-sbla-for-bullous-pemphigoid-treatment-under-priority-review/ 2025-02-19T12:07:59+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/rznomics-inc-liver-cancer-drug-receives-fast-track-designation/ 2025-02-19T12:10:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-full-approval-of-decipheras-romvimza-for-tgct-treatment/ 2025-02-19T12:12:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-breakthrough-therapy-designation-to-innate-pharmas-lacutamab-for-sezary-syndrome/ 2025-02-19T12:14:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-gsks-penmenvy-5-in-1-meningococcal-vaccine-for-menabcwy-protection/ 2025-02-19T12:16:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/fda-grants-immunitybio-approval-to-supply-recombinant-bcg-rbcg-amid-tice-bcg-shortage/ 2025-02-20T12:51:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/boehringers-zongertinib-gets-u-s-fda-priority-review-for-her2-mutant-advanced-nsclc/ 2025-02-20T12:52:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/ema-validates-gileads-application-for-twice-yearly-lenacapavir-as-hiv-prevention/ 2025-02-25T11:25:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/fda-accepts-bms-sblas-for-opdivo-yervoy-in-msi-high-mmr-d-cancer/ 2025-02-25T11:26:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/teva-and-alvotech-launch-selarsdi-injection-in-the-u-s/ 2025-02-25T11:29:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/mirums-ctexli-tablets-fda-approved-for-cerebrotendinous-xanthomatosis/ 2025-02-25T11:31:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/summit-therapeutics-partners-with-pfizer-to-trial-ivonescimab-with-adcs/ 2025-02-25T11:34:51+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/medigene-and-epimab-partner-on-co-development-of-tcr-guided-t-cell-engagers/ 2025-02-28T12:27:50+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-sobis-sbla-for-gamifant-emapalumab-lzsg/ 2025-02-28T12:29:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/sobi.png http://www.pharmajournalist.com/fda-accepts-bla-for-odronextamab-in-treating-relapsed-refractory-follicular-lymphoma/ 2025-02-28T12:31:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/lilly-to-exceed-50-billion-in-u-s-manufacturing-investment-doubling-since-2020/ 2025-02-28T12:33:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/redhill-licenses-rhb-102-to-hyloris-for-global-commercialization-potentially-worth-60m/ 2025-02-28T12:35:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/redhill-biopharma-logo.png http://www.pharmajournalist.com/sarclisa-approved-in-japan-for-newly-diagnosed-multiple-myeloma-patients/ 2025-02-28T12:37:29+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/fda-approves-genentechs-tnkase-for-acute-ischemic-stroke-in-adults/ 2025-03-04T11:59:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/Genentech-Image.jpg http://www.pharmajournalist.com/chmp-recommends-eu-approval-of-imfinzi-based-regimen-for-resectable-nsclc/ 2025-03-04T12:01:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/gensaic-partners-with-novo-nordisk-to-develop-next-gen-precision-therapies/ 2025-03-04T12:04:20+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/abbvie-and-gubra-strike-license-deal-to-develop-amylin-analog-for-obesity/ 2025-03-04T12:05:39+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/bridgebio-oncology-and-helix-acquisition-announce-business-merger-to-advance-ras-pi3k%ce%b1-medicines/ 2025-03-04T12:07:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/magnet-biomedicine-and-lilly-partner-to-develop-novel-molecular-glue-medicines/ 2025-03-04T12:09:18+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/wuxi-biologics-unveils-effix-platform-to-enhance-protein-and-dna-production/ 2025-03-04T12:11:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/wuxi-biologics-logo.png http://www.pharmajournalist.com/the-tumour-models-summit-hits-sweden/ 2025-03-07T11:32:15+00:00 https://pharmajournalist.com/wp-content/uploads/2025/03/Tumour-Models-Nordics-Infographic.jpg https://pharmajournalist.com/wp-content/uploads/2025/03/Tumour-Models-Nordics-Infographic.jpg http://www.pharmajournalist.com/plus-therapeutics-gets-fda-orphan-drug-status-for-obisbemeda-in-lung-cancer/ 2025-03-07T11:41:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/astellas-and-yaskawa-form-joint-venture-for-cell-therapy-manufacturing/ 2025-03-07T11:43:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/tris-pharma-announces-positive-alleviate-2-trial-results-for-cebranopadol/ 2025-03-07T11:47:19+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Tris-Pharma.jpg http://www.pharmajournalist.com/tc-biopharm-announces-letter-of-intent-to-acquire-ophthalmic-pharma-company/ 2025-03-07T11:49:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/novo-nordisk-launches-novocare-pharmacy-reduces-wegovy-cost-to-499-month/ 2025-03-07T11:52:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/ars-pharma-gets-fda-approval-for-neffy-1-mg-epinephrine-nasal-spray/ 2025-03-07T11:54:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/emergent-biosolutions-and-rocketvax-announce-investment-agreement-to-advance-next-generation-product-candidates/ 2025-03-13T18:59:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/vivace-therapeutics-secures-35-million-in-series-d-to-advance-first-in-class-cancer-drug/ 2025-03-13T19:00:48+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/lundbecks-msa-treatment-receives-orphan-drug-designation-in-japan/ 2025-03-13T19:02:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/lundbeck-logo.jpg http://www.pharmajournalist.com/wainzua-eplontersen-approved-in-the-eu-for-hereditary-transthyretin-mediated-amyloidosis/ 2025-03-13T19:04:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/ionis-pharma1.jpg http://www.pharmajournalist.com/elevatebio-partners-with-aws-to-enhance-crispr-gene-editing-with-generative-ai/ 2025-03-13T19:05:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/merck-reports-positive-phase-3-data-for-doravirine-islatravir-dor-isl-in-hiv-1-treatment/ 2025-03-13T19:07:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/zealand-pharma-and-roche-partner-to-co-develop-petrelintide-for-overweight-and-obesity-treatment/ 2025-03-13T19:09:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/latigo-biotherapeutics-secures-150-million-in-series-b-funding-to-propel-development-of-non-opioid-pain-treatments/ 2025-03-17T14:14:10+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/bristol-myers-squibb-gains-eu-approval-to-expand-breyanzi-car-t-therapy-for-follicular-lymphoma/ 2025-03-17T14:15:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/astrazeneca-to-acquire-esobiotec-to-boost-cell-therapy-goals/ 2025-03-17T14:18:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/astrazeneca-signs-license-deal-with-alteogen-for-subcutaneous-oncology-formulations/ 2025-03-17T14:19:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/salipro-biotech-and-boehringer-ingelheim-strike-research-and-license-deal-to-boost-pipeline-programs/ 2025-03-17T14:20:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/azurity-pharmaceuticals-acquires-covis-pharma/ 2025-03-17T14:21:48+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/menarini-partners-with-visualdx-to-identify-bpdcn/ 2025-03-21T13:05:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/servier-and-black-diamond-strike-licensing-deal-for-bdtx-4933/ 2025-03-21T13:08:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Servier-CDMO.png http://www.pharmajournalist.com/oxford-biotherapeutics-partners-with-roche-on-cancer-targets/ 2025-03-21T13:09:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/oxford-biomedica.jpg http://www.pharmajournalist.com/opko-health-and-entera-bio-partner-to-advance-oral-glp-1-tablet-for-obesity-and-metabolic-disorders/ 2025-03-21T13:13:24+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-alnylams-amvuttra-for-attr-cm/ 2025-03-21T13:16:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/novartis-gains-fda-approval-for-fabhalta-in-c3g/ 2025-03-21T13:18:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/altesa-biosciences-announces-clearance-of-investigational-new-drug-ind-application-for-vapendavir/ 2025-03-21T13:20:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/novo-holdings-joins-e23m-series-a-for-tribune-therapeutics-to-advance-anti-fibrotic-therapies/ 2025-03-27T14:00:26+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-approves-blujepa-for-uncomplicated-utis-in-women-and-kids-12/ 2025-03-27T14:02:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/gsk-uk-dri-hdr-uk-launch-dementia-research-initiative/ 2025-03-27T14:05:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/ema-accepts-gsks-nucala-copd-expansion-review/ 2025-03-27T14:06:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/fda-grants-fast-track-to-chlamydia-vaccine-candidate/ 2025-03-27T14:08:16+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/character-biosciences-raises-93m-series-b-for-eye-disease-precision-medicine/ 2025-03-27T14:09:56+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/european-commission-approves-mercks-capvaxive-for-pneumococcal-disease-in-adults/ 2025-03-27T14:13:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/united-laboratories-novo-nordisk-announce-exclusive-license-for-ubt251/ 2025-03-27T14:15:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/msd-secures-exclusive-license-for-hrs-5346-from-jiangsu-hengrui/ 2025-03-27T14:16:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/mercks-subcutaneous-pembrolizumab-shows-noninferior-pharmacokinetics-to-iv-keytruda/ 2025-03-28T12:06:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/soleno-therapeutics-wins-fda-approval-for-vykat-xr-to-treat-hyperphagia-in-prader-willi-syndrome/ 2025-03-28T12:08:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ionis-expands-partnership-with-sobi-for-olezarsen-commercialization-outside-the-u-s/ 2025-03-28T12:10:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/ionis-pharma1.jpg http://www.pharmajournalist.com/imfinzi-approved-as-first-perioperative-immunotherapy-for-bladder-cancer/ 2025-04-01T09:43:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/qfitlia-approved-as-first-us-therapy-for-hemophilia-a-b-with-or-without-inhibitors/ 2025-04-01T09:44:52+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/lexicon-pharmaceuticals-signs-exclusive-license-agreement-with-novo-nordisk-for-lx9851/ 2025-04-01T09:47:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/airna-secures-155m-in-oversubscribed-series-b-for-alpha-1-antitrypsin-trial/ 2025-04-02T11:45:18+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/apellis-gets-fda-priority-review-for-empaveli-in-c3g-ic-mpgn/ 2025-04-02T11:47:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/bavarian-nordic-gets-fda-approval-for-smallpox-mpox-vaccine/ 2025-04-02T11:48:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/eu-approves-pfizers-rsv-vaccine-abrysvo-for-adults-18-59/ 2025-04-02T11:50:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/amneal-launches-boruzu-first-ready-to-use-bortezomib-injection/ 2025-04-02T11:52:42+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/rilzabrutinib-receives-orphan-drug-designation-for-two-rare-diseases/ 2025-04-04T11:00:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/neurona-therapeutics-raises-102m-for-nrtx-1001-phase-3-trial/ 2025-04-04T11:02:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/boehringer-ingelheim-expands-adc-portfolio-with-new-rd-center-in-basel/ 2025-04-04T11:05:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/novartis-gets-fda-accelerated-approval-for-vanrafia-in-igan/ 2025-04-04T11:07:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/astellas-partners-with-japanese-cancer-foundation-to-boost-oncology-research/ 2025-04-04T11:09:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/sangamo-and-lilly-partner-on-capsid-license-for-cns-genomic-medicines/ 2025-04-04T11:12:14+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/flagship-pioneering-and-pfizer-partner-to-develop-selective-inhibitors-for-autoimmune-diseases/ 2025-04-04T11:14:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ethris-and-lonza-partner-on-spray-dried-mrna-vaccines-for-respiratory-diseases/ 2025-04-09T10:44:44+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/engine-biosciences-and-eddc-partner-to-advance-cancer-therapies/ 2025-04-09T10:46:09+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/cas-and-cleveland-clinic-collaborate-to-boost-research-with-ai-and-quantum-computing/ 2025-04-09T10:47:49+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/avidity-biosciences-wins-orphan-drug-designation-in-japan-for-delpacibart-etedesiran/ 2025-04-09T10:49:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/abl-bio-signs-license-deal-with-gsk-for-grabody-b-brain-delivery-platform/ 2025-04-09T10:55:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/alx-oncology-gets-fda-ind-clearance-for-egfr-targeted-antibody-drug-conjugate-alx2004/ 2025-04-09T10:57:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/uplizna-becomes-first-fda-approved-treatment-for-igg4-related-disease/ 2025-04-09T10:59:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/epsilogen-acquires-tigatx-to-lead-pan-isotype-cancer-antibody-market/ 2025-04-09T11:01:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/poxel-gains-approval-to-expand-twymeeg-indication-for-type-2-diabetes-with-renal-impairment-in-japan/ 2025-04-09T11:05:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/fda-to-phase-out-animal-testing-requirement-for-monoclonal-antibodies-and-drugs/ 2025-04-11T12:06:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-biocons-jobevne-bevacizumab-biosimilar/ 2025-04-11T12:11:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/cingulate-secures-3m-grant-to-advance-anxiety-drug-ctx-2103-buspirone/ 2025-04-11T12:14:22+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/argenx-wins-fda-approval-for-vyvgart-hytrulo-self-injection/ 2025-04-11T12:27:13+00:00 https://pharmajournalist.com/wp-content/uploads/2025/04/argenx-image.webp http://www.pharmajournalist.com/renovaro-and-biosymetrics-complete-merger-to-boost-ai-driven-biomarker-discovery-and-precision-medicine/ 2025-04-11T12:29:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-cue-biopharma-team-up-on-next-gen-autoimmune-therapies/ 2025-04-16T10:15:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/bristol-myers-squibb-shares-phase-3-odyssey-hcm-trial-update/ 2025-04-16T10:17:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/ironwood-pharmaceuticals-issues-clinical-and-regulatory-update-on-apraglutide/ 2025-04-16T10:19:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/valneva-secures-first-ixchiq-approval-in-chikungunya-endemic-country/ 2025-04-16T10:21:51+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/reveal-genomics-and-ona-therapeutics-partner-on-next-gen-cancer-therapy/ 2025-04-16T10:23:33+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pfizer-shares-update-on-oral-glp-1-candidate-danuglipron/ 2025-04-16T10:25:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/eu-approves-roches-columvi-as-first-bispecific-antibody-for-dlbcl-after-initial-treatment/ 2025-04-16T10:27:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/cellino-and-karis-bio-partner-to-develop-first-nebula-powered-ipsc-therapy-for-heart-disease/ 2025-04-16T10:33:57+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/daan-biotherapeutics-and-gc-cell-sign-deal-to-transfer-tumor-antigen-antibody-tech-for-next-gen-car-t-nk-therapies/ 2025-04-22T12:31:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/uniqures-amt-130-gets-fda-breakthrough-tag-for-huntingtons/ 2025-04-22T12:33:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/uniqure.jpg http://www.pharmajournalist.com/dupixent-approved-in-u-s-as-first-targeted-therapy-in-over-a-decade-for-chronic-hives/ 2025-04-22T12:35:29+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/bighat-and-lilly-team-up-to-develop-ai-driven-antibody-therapies/ 2025-04-22T12:37:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/roche-to-invest-50b-in-u-s-pharma-and-diagnostics-over-5-years/ 2025-04-22T12:39:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/ono-and-jorna-launch-collaboration-on-novel-rna-editing-therapies/ 2025-04-22T12:41:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/granite-bio-debuts-with-100-million-of-capital/ 2025-04-25T13:12:44+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/repertoire-immune-and-genentech-partner-on-t-cell-targeted-autoimmune-therapies/ 2025-04-25T13:15:12+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-tessellate-bio-partner-on-precision-treatments-for-hard-to-treat-cancers/ 2025-04-25T13:17:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/concertai-partners-with-bayer-to-advance-precision-oncology-clinical-development/ 2025-04-25T13:19:09+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/regeneron-invests-in-expanding-biologic-medicine-manufacturing/ 2025-04-25T13:20:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/debiopharm-and-oncodesign-partner-to-boost-radiopharmaceuticals-in-preclinical-research/ 2025-04-25T13:22:20+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/oxford-boehringer-cumulus-launch-first-ever-study-on-daily-life-with-psychiatric-disorders/ 2025-04-30T13:13:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/fda-approves-rinvoq-for-giant-cell-arteritis/ 2025-04-30T13:16:00+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/fda-approves-zevaskyn-first-cell-based-gene-therapy-for-rdeb/ 2025-04-30T13:18:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/merck-breaks-ground-on-1b-biologics-center-in-delaware/ 2025-04-30T13:21:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/biohaven-secures-up-to-600m-investment-from-oberland-capital/ 2025-04-30T13:25:04+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/prilenia-partners-with-ferrer-for-pridopidine-in-europe-and-beyond/ 2025-04-30T13:26:36+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/qiagen-expands-digital-pcr-portfolio-with-new-lentivirus-solutions/ 2025-04-30T13:29:08+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/qiagen-image.jpg http://www.pharmajournalist.com/creyon-bio-and-lilly-partner-on-rna-targeted-oligo-therapy/ 2025-04-30T13:31:19+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/veraxa-and-omniab-partner-to-develop-novel-bispecific-antibody-drug-conjugate/ 2025-05-06T13:50:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/teva-and-alvotech-gain-fda-interchangeability-for-selarsdi-biosimilar-to-stelara/ 2025-05-06T13:57:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/tae-life-sciences-and-ohio-state-partner-on-boron-drug-innovation-for-cancer-therapy/ 2025-05-06T13:59:14+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/oral-semaglutide-25-mg-filing-accepted-by-fda-could-be-first-oral-glp-1-for-obesity/ 2025-05-06T14:01:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/fda-grants-fast-track-for-alteritys-ath434-in-multiple-system-atrophy-treatment/ 2025-05-06T14:03:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/illumina-ovation-io-launch-novel-glp-1-dataset-for-faster-therapy-development/ 2025-05-06T14:07:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-johnson-johnsons-imaavy-for-broad-generalized-myasthenia-gravis-population/ 2025-05-06T14:11:15+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/speaker-interview-with-anna-karmann-chief-medical-officer-advancell/ 2025-05-06T14:16:17+00:00 https://pharmajournalist.com/wp-content/uploads/2025/03/55198-Pharma-J-Banner.jpg http://www.pharmajournalist.com/haya-therapeutics-secures-65m-series-a-to-advance-rna-guided-therapies-for-chronic-diseases/ 2025-05-09T08:39:35+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/biovaxys-and-sona-nanotech-enter-research-collaboration/ 2025-05-09T08:44:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/opus-genetics-opgx-lca5-gene-therapy-earns-fda-rmat-designation/ 2025-05-09T08:46:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/amneal-and-apiject-partner-to-boost-u-s-sterile-bfs-manufacturing-capacity/ 2025-05-09T08:47:57+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/adcentrxs-adrx-0706-nectin-4-adc-earns-fda-fast-track-for-advanced-cervical-cancer/ 2025-05-09T08:49:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/genezen-and-optieum-partner-to-advance-cgmp-manufacturing-for-glioblastoma-car-t-therapy/ 2025-05-09T08:51:33+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/biodexa-receives-orphan-drug-designation-in-europe-for-erapa-in-fap/ 2025-05-13T12:15:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/perjeta-regimen-cuts-death-risk-by-17-in-her2-breast-cancer/ 2025-05-13T12:19:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/novo-nordisks-once-weekly-sogroya-proves-effective-in-children-with-growth-disorders/ 2025-05-13T12:23:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/trixeo-aerosphere-approved-in-uk-as-first-inhaled-respiratory-drug-with-near-zero-gwp-propellant/ 2025-05-13T12:26:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/beam-therapeutics-beam-302-granted-rmat-designation-by-fda-for-aatd-treatment/ 2025-05-13T12:28:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/injectable-drug-delivery-2025-driving-innovation-through-collaboration/ 2025-05-13T19:18:10+00:00 https://pharmajournalist.com/wp-content/uploads/2025/05/SAE-Media.png http://www.pharmajournalist.com/fda-approves-emrelis-for-advanced-nsclc-with-high-c-met/ 2025-05-16T04:39:23+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/fda-accepts-biocrysts-nda-for-orladeyo-in-young-hae-patients/ 2025-05-16T04:40:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-adarx-partner-on-next-gen-sirna-therapies/ 2025-05-16T04:42:10+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/tempus-boehringer-ingelheim-launch-cancer-collaboration/ 2025-05-16T04:44:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/septerna-novo-nordisk-partner-on-oral-treatments-for-obesity-and-cardiometabolic-diseases/ 2025-05-16T04:46:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/recipharm-and-plg-form-partnership-to-accelerate-drug-development/ 2025-05-16T04:48:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/recipharm.jpg http://www.pharmajournalist.com/gsk-to-acquire-efimosfermin-for-steatotic-liver-disease/ 2025-05-16T04:50:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/stylus-medicine-launches-to-advance-precision-in-vivo-car-t-therapies/ 2025-05-16T04:52:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/pfizer-signs-exclusive-licensing-deal-with-3sbio/ 2025-05-20T09:34:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/bristol-myers-squibb-wins-eu-approval-for-opdivo-based-lung-cancer-regimen/ 2025-05-20T09:36:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/biomarin-acquires-inozyme-to-boost-enzyme-therapy-portfolio/ 2025-05-20T09:38:57+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ucb-partners-with-domino-data-lab-to-modernize-life-sciences-computing/ 2025-05-20T09:41:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/fda-approves-novavaxs-covid-19-vaccine-bla/ 2025-05-20T09:43:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/iqvia-and-scri-partner-to-speed-up-global-oncology-trials/ 2025-05-20T09:46:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/celebrating-a-decade-of-innovation-the-10th-microbiome-movement-drug-development-summit/ 2025-05-20T10:16:22+00:00 https://pharmajournalist.com/wp-content/uploads/2025/03/59621_Pharma-J.gif http://www.pharmajournalist.com/spotlight-on-emerging-innovators-the-2025-start-up-showcase/ 2025-05-28T06:17:04+00:00 https://pharmajournalist.com/wp-content/uploads/2025/05/Start-up-Showcase-Article-2.png https://pharmajournalist.com/wp-content/uploads/2025/05/Start-up-Showcase-Article-2.png http://www.pharmajournalist.com/lilly-boosts-pain-pipeline-with-siteone-therapeutics-acquisition/ 2025-05-28T06:19:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/lupin-steincares-ink-ranibizumab-deal-for-latin-america/ 2025-05-28T06:20:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/lupin-pharma.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-otsukas-sibeprenlimab-for-igan/ 2025-05-28T06:22:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/otsuka-europe.jpg http://www.pharmajournalist.com/health-canada-to-review-gsks-depemokimab-for-asthma-and-nasal-polyps/ 2025-05-28T06:24:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/askbio-publishes-full-phase-1b-results-for-parkinsons-gene-therapy-ab-1005/ 2025-05-28T06:27:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/biogen-and-city-therapeutics-launch-collaboration-to-develop-rnai-based-therapies/ 2025-05-28T06:31:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/tevas-celiac-disease-drug-receives-fda-fast-track-designation/ 2025-05-28T06:33:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/TEVA-Pharma.jpg http://www.pharmajournalist.com/circode-biomed-gets-fda-clearance-for-first-circular-rna-drug-hm2002/ 2025-06-03T07:08:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/astellas-licenses-xnw27011-adc-from-evopoint-biosciences/ 2025-06-03T07:13:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/immunitybio-gets-fda-expanded-access-for-anktiva-in-solid-tumors/ 2025-06-03T07:15:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/modernas-mnexspike-covid-19-vaccine-wins-fda-approval/ 2025-06-03T07:17:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/honoring-excellence-the-10th-annual-microbiome-movement-awards/ 2025-06-03T07:21:03+00:00 https://pharmajournalist.com/wp-content/uploads/2025/06/10-Year-Anniversary-Article-3.png https://pharmajournalist.com/wp-content/uploads/2025/06/10-Year-Anniversary-Article-3.png http://www.pharmajournalist.com/eu-approves-roches-evrysdi-as-first-oral-treatment-for-sma/ 2025-06-04T11:40:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/spyglass-pharma-raises-75m-to-advance-glaucoma-drug-delivery-platform/ 2025-06-04T11:41:30+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/eu-approves-adcetris-combo-for-newly-diagnosed-advanced-hodgkin-lymphoma/ 2025-06-04T11:42:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/regeneron-boosts-obesity-pipeline-with-dual-glp-1-gip-agonist-deal/ 2025-06-04T11:44:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/fda-approves-nubeqa-for-metastatic-prostate-cancer/ 2025-06-04T11:47:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/camurus-and-lilly-partner-on-long-acting-fluidcrystal-incretins/ 2025-06-06T11:10:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/alnylams-amvuttra-wins-eu-approval-for-attr-amyloidosis-with-cardiomyopathy/ 2025-06-10T10:49:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/aytu-biopharma-secures-exclusive-us-rights-for-novel-antidepressant-exxua/ 2025-06-10T10:52:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/eu-approves-fixed-duration-calquence-regimens-for-1st-line-cll/ 2025-06-10T10:53:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/yoltech-therapeutics-gets-fda-green-light-for-gene-editing-therapy-yolt-101-for-hefh/ 2025-06-10T10:55:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/enhancing-collaboration-networking-opportunities-at-the-summit/ 2025-06-10T11:21:11+00:00 https://pharmajournalist.com/wp-content/uploads/2025/06/Networking-Article-4.png https://pharmajournalist.com/wp-content/uploads/2025/06/Networking-Article-4.png http://www.pharmajournalist.com/splicebio-raises-135m-series-b-to-advance-sb-007-for-stargardt-disease/ 2025-06-13T09:58:13+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/echosens-and-boehringer-ingelheim-expand-partnership-to-advance-mash-diagnosis-and-care/ 2025-06-13T10:01:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/exploring-new-frontiers-innovations-in-microbiome-therapeutics/ 2025-06-17T19:58:53+00:00 https://pharmajournalist.com/wp-content/uploads/2025/06/Innovation-Article-5.png https://pharmajournalist.com/wp-content/uploads/2025/06/Innovation-Article-5.png http://www.pharmajournalist.com/lisata-and-gatc-health-expand-partnership-for-ai-driven-drug-discovery/ 2025-06-18T13:48:41+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/averoa-wins-eu-approval-for-xoanacyl-oral-ckd-therapy/ 2025-06-18T13:53:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/bioaegis-gets-fda-fast-track-for-ards-treatment-with-gelsolin/ 2025-06-18T13:55:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/teva-and-fosun-partner-to-develop-novel-anti-pd1-il2-cancer-therapy/ 2025-06-18T14:01:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/nextcure-and-simcere-zaiming-partner-on-novel-cdh6-targeting-adc/ 2025-06-18T14:04:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/celltrion-secures-fda-approval-for-new-steqeyma-pediatric-dosing-option/ 2025-06-18T14:05:56+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/celltrion-Image.png http://www.pharmajournalist.com/actio-biosciences-raises-66m-in-series-b-to-advance-genetics-based-therapies/ 2025-06-20T11:20:48+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/draig-therapeutics-launches-with-140m-to-tackle-neuropsychiatric-disorders/ 2025-06-20T11:23:00+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/yeztugo-becomes-first-fda-approved-hiv-prevention-with-6-month-protection/ 2025-06-20T11:25:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/rybodyn-joins-lilly-gateway-labs-to-advance-immunotherapies-targeting-dark-proteome/ 2025-06-20T11:28:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/advarra-launches-ai-council-to-boost-innovation-in-clinical-trials/ 2025-06-20T11:29:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/jj-seeks-fda-approval-of-stelara-for-pediatric-crohns-disease/ 2025-06-20T11:32:39+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/fnp-223-receives-fda-fast-track-designation-for-progressive-supranuclear-palsy/ 2025-06-20T11:35:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/cellular-origins-partners-with-thermo-fisher-to-revolutionize-cgt-manufacturing-with-automated-robotics/ 2025-06-20T11:38:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/coherus-and-storm-therapeutics-partner-to-evaluate-stc-15-with-loqtorzi-in-clinical-trial/ 2025-06-20T11:40:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/novo-nordisk-advances-amycretin-for-weight-loss-to-phase-3-trials/ 2025-06-20T11:41:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/itepekimab-hits-primary-goal-in-one-of-two-copd-phase-3-trials/ 2025-06-20T11:41:43+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/dynes-dyne-101-earns-fda-breakthrough-status-eyes-accelerated-dm1-approval/ 2025-06-20T11:42:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/lilly-to-acquire-verve-therapeutics-for-one-time-cardiovascular-treatments/ 2025-06-20T11:43:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/orion-and-glykos-extend-collaboration-on-next-gen-adc-development/ 2025-06-20T11:43:43+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-mavyret-as-first-treatment-for-acute-hepatitis-c/ 2025-06-20T11:43:51+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/fda-approves-mercks-enflonsia-for-rsv-prevention-in-infants/ 2025-06-20T11:44:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/vividion-and-bayer-advance-oncology-pipeline-with-clinical-stage-wrn-inhibitor/ 2025-06-20T11:44:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/wuxi-biologics-begins-construction-of-chengdu-microbial-manufacturing-facility/ 2025-06-20T11:45:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/wuxi-biologics-logo.png http://www.pharmajournalist.com/lupin-and-sino-universal-partner-to-supply-tiotropium-dpi-in-china/ 2025-06-20T11:45:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/lupin-pharma.jpg http://www.pharmajournalist.com/capsida-to-begin-phase-1-2-trial-of-cap-003-in-q3/ 2025-06-20T11:46:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/biontech-to-acquire-curevac-in-strategic-public-exchange-deal/ 2025-06-20T11:46:17+00:00 https://pharmajournalist.com/wp-content/uploads/2018/08/BioNTech-AG.jpg http://www.pharmajournalist.com/cellectar-receives-fda-breakthrough-designation-for-iopofosine-in-wm/ 2025-06-20T11:46:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/agenus-zydus-ink-141m-deal-to-advance-bot-bal-expand-u-s-biologics-production/ 2025-06-20T11:46:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agenus.jpg http://www.pharmajournalist.com/biontech-bms-launch-global-partnership-to-develop-cancer-therapy-bnt327/ 2025-06-20T11:47:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/BioNTech.jpg http://www.pharmajournalist.com/sanofi-to-acquire-blueprint-medicines-boosting-rare-disease-and-immunology-pipeline/ 2025-06-20T11:47:51+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/harbour-biomed-and-otsuka-partner-globally-to-develop-bcmaxcd3-bispecific-t-cell-engagers/ 2025-06-24T10:41:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/argenx-wins-eu-approval-for-vyvgart-sc-to-treat-cidp/ 2025-06-24T10:43:32+00:00 https://pharmajournalist.com/wp-content/uploads/2025/04/argenx-image.webp http://www.pharmajournalist.com/health-canada-approves-novartis-kisqali-for-high-risk-early-breast-cancer/ 2025-06-24T10:45:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/datroway-approved-in-u-s-for-advanced-egfr-mutated-lung-cancer/ 2025-06-24T10:47:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/novo-nordisks-ozempic-recommended-by-eu-for-peripheral-arterial-disease-in-type-2-diabetes/ 2025-06-24T10:52:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/archeus-technologies-gets-fda-clearance-for-art-101-prostate-cancer-trial/ 2025-06-24T10:54:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/porton-advanced-eva-pharma-sign-mou-to-expand-car-t-cell-therapy-in-mea-region/ 2025-06-27T09:31:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/vor-bio-remegen-sign-exclusive-global-license-deal-for-late-stage-autoimmune-therapy/ 2025-06-27T09:34:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-approves-updated-label-for-lillys-amyvid-to-aid-alzheimers-diagnosis/ 2025-06-27T09:35:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/novartis-completes-acquisition-of-regulus-therapeutics/ 2025-06-27T09:38:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/gilead-and-kymera-partner-on-novel-oral-cdk2-degraders-in-exclusive-license-deal/ 2025-06-27T09:40:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/fda-approves-benlysta-autoinjector-for-pediatric-lupus-nephritis/ 2025-06-27T09:42:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/fda-expands-ge-healthcares-vizamyl-indications-for-enhanced-alzheimers-beta-amyloid-detection/ 2025-06-27T09:44:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/mederas-novoheart-teams-up-to-develop-mini-heart-models-for-hypoplastic-left-heart-syndrome-treatment/ 2025-06-27T10:08:51+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/profound-therapeutics-novartis-announce-multi-year-cardiovascular-collaboration/ 2025-06-27T10:11:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/bayer-extends-partnership-with-tsinghua-university-to-boost-pharma-research-in-china/ 2025-06-27T10:12:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/abbvie-to-acquire-capstan-therapeutics-advancing-immunology-innovation/ 2025-07-01T12:29:48+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/piramal-pharma-solutions-breaks-ground-on-90m-expansion/ 2025-07-01T12:31:21+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/vetter-breaks-ground-on-new-clinical-site/ 2025-07-01T12:33:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/01/Vetter-Pharma.jpg http://www.pharmajournalist.com/fda-eases-monitoring-rules-removes-rems-from-bms-cell-therapies/ 2025-07-01T12:34:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/fda-approves-gamifant-as-first-treatment-for-mas-in-stills-disease/ 2025-07-01T12:36:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/sobi.png http://www.pharmajournalist.com/fda-approves-takedas-gammagard-liquid-erc-first-low-iga-ready-to-use-therapy/ 2025-07-01T12:43:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/lynozyfic-linvoseltamab-gcpt-granted-fda-accelerated-approval-for-relapsed-refractory-multiple-myeloma/ 2025-07-03T13:55:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/riliprubart-earns-orphan-drug-designation-in-japan-for-cidp/ 2025-07-03T13:57:24+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/adagene-secures-up-to-25m-strategic-investment-from-sanofi/ 2025-07-03T13:59:15+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-grants-accelerated-approval-to-zegfrovy-first-oral-egfr%e2%80%91exon%e2%80%9120-insertion-nsclc-therapy/ 2025-07-03T14:01:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-priority-review-for-winrevair-label-update-following-zenith-trial-results/ 2025-07-03T14:04:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/jazz-pharmaceuticals-gets-eu-approval-for-ziihera-to-treat-advanced-her2-positive-biliary-tract-cancer/ 2025-07-03T14:06:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/jazz-pharmaceuticals.jpg http://www.pharmajournalist.com/brii-biosciences-licenses-brii-693-rights-to-joincare-in-greater-china/ 2025-07-04T10:44:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/bioversys-and-shionogi-partner-on-global-ntm-drug-development-collaboration/ 2025-07-04T10:46:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/abbvie-and-igi-ink-global-deal-for-first-in-class-trispecific-antibody-isb-2001/ 2025-07-11T12:11:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/lupin-and-zentiva-ink-licensing-deal-to-commercialize-certolizumab-in-europe/ 2025-07-11T12:13:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/lupin-pharma.jpg http://www.pharmajournalist.com/merck-to-acquire-verona-pharma-adding-first-in-class-copd-drug-ohtuvayre-to-pipeline/ 2025-07-11T12:22:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/fda-approves-merck-animal-healths-bravecto-quantum-injectable-for-flea-and-tick-protection/ 2025-07-11T12:24:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/transcend-therapeutics-gets-breakthrough-therapy-designation-for-tsnd-201-in-ptsd/ 2025-07-11T12:26:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/gsk-completes-acquisition-of-efimosfermin-to-combat-steatotic-liver-disease/ 2025-07-11T12:28:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/kalvistas-ekterly-gets-fda-nod-as-first-oral-on-demand-hereditary-angioedema-treatment/ 2025-07-11T12:31:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/biocytogen-signs-antibody-licensing-deal-with-beone-medicines-to-boost-drug-development/ 2025-07-11T12:34:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/neuraxpharm-and-dizlin-partner-to-develop-next-gen-therapy-for-advanced-parkinsons-disease/ 2025-07-11T12:36:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-status-to-adcentrxs-adrx-0405-for-gastric-cancer/ 2025-07-11T12:38:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/mustang-bios-mb-101-receives-fda-orphan-drug-designation-for-astrocytomas-and-glioblastoma/ 2025-07-11T12:40:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/mustang-bio-logo.jpg http://www.pharmajournalist.com/chugai-and-gero-partner-to-develop-novel-age-related-disease-therapies/ 2025-07-11T12:42:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/secarna-pharmaceuticals-and-vect-horus-partner-to-boost-rna-therapeutics-delivery-for-cns-disorders/ 2025-07-11T12:44:14+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sagent-and-qilu-forge-strategic-partnership-to-boost-access-to-critical-injectables-in-u-s/ 2025-07-11T12:46:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/thermo-fisher-and-sanofi-expand-u-s-drug-manufacturing-partnership/ 2025-07-17T10:44:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/fda-approves-gsks-shingrix-in-prefilled-syringe-format/ 2025-07-17T10:46:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/navamedic-finalizes-acquisition-of-dne-pharma-business/ 2025-07-17T10:49:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/acumen-and-jcr-partner-to-develop-enhanced-brain-delivery-alzheimers-therapy/ 2025-07-17T10:51:44+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/otsuka-acquires-global-rights-to-cantargias-can10-for-autoimmune-disease-treatment/ 2025-07-17T10:54:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/otsuka-europe.jpg http://www.pharmajournalist.com/vertex-secures-nhs-england-reimbursement-for-once-daily-cftr-modulator-alyftrek/ 2025-07-17T10:56:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-leo-pharma-partner-to-commercialize-and-develop-spevigo/ 2025-07-17T10:58:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/leo-pharma.jpg http://www.pharmajournalist.com/repare-therapeutics-signs-exclusive-global-license-deal-with-debiopharm-for-lunresertib/ 2025-07-17T11:00:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/astellas-partners-with-koreas-kised-to-support-drug-discovery-startups/ 2025-07-18T12:33:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/aldeyras-dry-eye-drug-nda-accepted-for-fda-review/ 2025-07-18T12:35:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/rocket-pharmas-rp-a601-gene-therapy-granted-fda-rmat-designation-for-pkp2-acm/ 2025-07-18T12:37:49+00:00 https://pharmajournalist.com/wp-content/uploads/2021/01/Rocket-Pharmaceuticals-Headquarters.jpg http://www.pharmajournalist.com/endeavor-biomedicines-taladegib-granted-orphan-drug-status-in-u-s-and-eu-for-ipf/ 2025-07-18T12:40:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/enhertu-plus-pertuzumab-granted-u-s-breakthrough-therapy-status-for-her2-metastatic-breast-cancer/ 2025-07-18T12:44:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/sanofis-sar446597-granted-fda-fast-track-for-geographic-atrophy-in-amd/ 2025-07-18T12:46:02+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/alzecures-acd440-pain-therapy-receives-fda-orphan-drug-designation/ 2025-07-18T12:47:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/kling-bio-and-sanofi-partner-to-fast-track-neutralizing-antibody-discovery/ 2025-07-24T10:56:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/astrazeneca-to-invest-50-billion-in-u-s-for-drug-manufacturing-and-rd/ 2025-07-24T10:59:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/gefurulimab-shows-significant-improvement-in-daily-function-for-gmg-patients-in-phase-iii-prevail-trial/ 2025-07-24T11:01:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/sanofi-to-acquire-vicebio-boosting-respiratory-vaccine-portfolio/ 2025-07-24T11:05:17+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/jj-seeks-first-fda-approval-for-icotrokinra-to-treat-plaque-psoriasis/ 2025-07-24T11:10:15+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/sarepta-therapeutics-announces-voluntary-pause-of-elevidys-shipments-in-the-u-s/ 2025-07-24T11:12:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Sarepta-Therapeutics.jpg http://www.pharmajournalist.com/european-commission-approves-darzalex-as-first-licensed-treatment-for-high-risk-smouldering-multiple-myeloma/ 2025-07-24T11:15:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/09/Janssen.jpg http://www.pharmajournalist.com/solid-biosciences-earns-fda-fast-track-for-sgt-501-gene-therapy-in-cpvt/ 2025-07-24T11:18:45+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/solid-biosciences.jpg http://www.pharmajournalist.com/sutro-biopharma-partners-with-fda-to-advance-antibody-drug-conjugate-regulatory-standards/ 2025-07-24T11:20:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ausperbio-secures-china-cde-clearance-to-launch-phase-iii-trial-for-ahb-137-in-chronic-hepatitis-b/ 2025-07-24T11:29:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/promis-neurosciences-receives-fda-fast-track-designation-for-pmn310-alzheimers-treatment/ 2025-07-24T11:31:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/pfizer-and-biontech-covid-19-vaccine-adapted-for-lp-8-1-variant-receives-positive-chmp-opinion-in-eu/ 2025-07-25T11:49:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/pfizer-and-3sbio-finalize-licensing-deal/ 2025-07-25T11:52:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/eu-approves-blenrep-combinations-for-relapsed-refractory-multiple-myeloma/ 2025-07-25T11:56:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/eu-regulators-back-alhemo-label-expansion-for-haemophilia-a-and-b-without-inhibitors/ 2025-07-25T11:59:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/strategic-partnership-formed-with-allianthera-suzhou-biopharmaceuticals/ 2025-07-31T10:47:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/gsk-and-hengrui-pharma-partner-to-develop-up-to-12-innovative-medicines-in-key-therapeutic-areas/ 2025-07-31T10:50:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/virocell-and-avencell-partner-on-retroviral-vector-manufacturing-for-next-gen-car-t-blood-cancer-therapies/ 2025-07-31T10:53:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/viridian-and-kissei-partner-to-develop-veligrotug-and-vrdn-003-in-japan-in-385m-deal/ 2025-07-31T10:54:56+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-re-vana-partner-to-develop-long-acting-eye-disease-therapies/ 2025-07-31T10:57:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/fda-advises-sarepta-to-lift-pause-and-resume-elevidys-shipments-for-ambulatory-duchenne-patients/ 2025-07-31T11:00:32+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Sarepta-Therapeutics.jpg http://www.pharmajournalist.com/fda-approves-skytrofa-for-once-weekly-adult-growth-hormone-deficiency-treatment/ 2025-07-31T11:03:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/gileads-twice-yearly-lenacapavir-gets-positive-chmp-opinion-for-hiv-prevention/ 2025-07-31T11:05:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/astrazeneca-and-revna-biosciences-expand-lung-cancer-treatment-access-in-ghana/ 2025-07-31T11:07:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/madrigal-pharmaceuticals-secures-exclusive-global-license-for-oral-glp-1-agonist-with-cspc-pharmaceutical/ 2025-07-31T11:09:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/lillys-mounjaro-shows-heart-benefits-in-landmark-trial-for-type-2-diabetes-patients/ 2025-08-01T11:58:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/altasciences-and-voxcell-partner-to-boost-preclinical-drug-development/ 2025-08-01T12:02:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/repligen-and-novasign-partner-to-drive-bioprocessing-digitalization/ 2025-08-01T12:04:33+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/agios-pyrukynd-mitapivat-approved-in-saudi-arabia-for-adult-thalassemia-patients/ 2025-08-05T12:29:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/sandoz-to-acquire-just-evotec-biologics-facility-in-toulouse-under-new-term-sheet/ 2025-08-05T12:32:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/atombeat-and-bioduro-partner-to-launch-ai-platform-for-faster-peptide-drug-discovery/ 2025-08-05T12:34:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/the-3rd-spatial-biology-for-drug-development-summit-free-to-attend-for-biopharma-experts/ 2025-08-07T12:05:28+00:00 https://pharmajournalist.com/wp-content/uploads/2025/07/Spatial-Biology-for-DD-Pharma-Journalist.jpg http://www.pharmajournalist.com/fda-approves-jazz-pharmas-modeyso-as-first-treatment-for-recurrent-h3-k27m-mutant-brain-cancer/ 2025-08-07T12:19:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/jazz-pharmaceuticals.jpg http://www.pharmajournalist.com/fda-expands-approval-of-ajovy-as-first-anti-cgrp-preventive-for-pediatric-episodic-migraine/ 2025-08-07T12:21:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/fresenius-polpharma-biologics-ink-deal-to-commercialize-vedolizumab-biosimilar/ 2025-08-07T12:24:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/Fresenius-Kabi.jpg http://www.pharmajournalist.com/astria-kaken-ink-licensing-deal-to-develop-navenibart-for-hae-in-japan/ 2025-08-07T12:26:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/serb-pharmaceuticals-to-acquire-y-mabs-therapeutics-in-strategic-deal/ 2025-08-07T12:28:36+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/axplora-announces-e6-5m-investment-in-vizag-facility-and-fda-inspection-success-in-india/ 2025-08-07T12:30:15+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-accepts-bristol-myers-squibbs-priority-review-for-breyanzi-in-relapsed-refractory-marginal-zone-lymphoma/ 2025-08-07T12:32:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/cingulate-files-fda-new-drug-application-for-lead-adhd-drug-ctx-1301/ 2025-08-07T12:34:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/genmabs-epcore-fl-1-trial-meets-goals-in-r-r-fl/ 2025-08-08T11:36:27+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/Genmab-Logo.jpg http://www.pharmajournalist.com/valneva-fda-lifts-pause-on-ixchiq-for-elderly-updates-prescribing-info/ 2025-08-08T11:40:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/cormedix-to-acquire-melinta-expanding-acute-care-portfolio/ 2025-08-08T11:42:44+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/ono-and-seikagaku-partner-to-co-develop-and-market-gel-one-for-osteoarthritis-in-japan/ 2025-08-08T11:44:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sartorius-stedim-biotech-and-nanotein-partner-to-boost-cell-therapy-manufacturing/ 2025-08-12T10:55:45+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-gepotidacin-for-oral-treatment-of-gonorrhea/ 2025-08-12T10:57:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/fda-grants-accelerated-approval-to-boehringers-hernexeos-for-her2-mutant-lung-cancer/ 2025-08-12T11:00:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/fda-accepts-arvinas-nda-for-vepdegestrant-in-er-her2-breast-cancer-with-esr1-mutation/ 2025-08-12T11:02:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/viatris-receives-fda-approval-for-first-generic-iron-sucrose-injection-in-u-s/ 2025-08-12T11:05:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/kexing-biopharm-partners-with-iqvia-to-drive-global-expansion/ 2025-08-12T11:07:41+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/madrigals-rezdiffra-approved-in-eu-for-mash-treatment/ 2025-08-20T12:46:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.png http://www.pharmajournalist.com/fda-grants-breakthrough-status-to-izalontamab-brengitecan-for-egfr-mutant-lung-cancer/ 2025-08-20T12:48:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/santen-remegen-ink-licensing-deal-for-dual-target-eye-drug-rc28-e/ 2025-08-20T12:51:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ptc-therapeutics-gets-fda-complete-response-letter-for-vatiquinone-nda/ 2025-08-20T12:53:29+00:00 https://pharmajournalist.com/wp-content/uploads/2020/05/PTC-Therapeutics.jpg http://www.pharmajournalist.com/european-commission-approves-ogsiveo-for-adult-desmoid-tumors/ 2025-08-20T12:55:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/boehringer-ingelheim-anges-ink-manufacturing-deal-for-hgf-gene-therapy/ 2025-08-20T12:57:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/boehringer-ingelheim-palatin-technologies-partner-to-develop-melanocortin-receptor-therapy-for-retinal-diseases/ 2025-08-20T12:59:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/precigens-papzimeos-gets-full-fda-approval-for-recurrent-respiratory-papillomatosis/ 2025-08-20T13:01:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/dawnzera-donidalorsen-becomes-first-fda-approved-rna-targeted-prophylactic-for-hereditary-angioedema/ 2025-08-22T10:53:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/ionis-pharma1.jpg http://www.pharmajournalist.com/andelyn-biosciences-and-amplo-biotech-partner-to-advance-gene-therapies-for-neuromuscular-junction-disorders/ 2025-08-22T10:55:01+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/johnson-johnson-invests-2b-in-new-state-of-the-art-manufacturing-facility-in-north-carolina/ 2025-08-22T10:57:00+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/kite-to-acquire-interius-biotherapeutics-to-expand-in-vivo-cell-therapy-capabilities/ 2025-08-22T11:00:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-designation-to-keros-ker-065-for-duchenne-muscular-dystrophy/ 2025-08-22T11:02:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-designation-to-crinetics-atumelnant-for-congenital-adrenal-hyperplasia/ 2025-08-22T11:04:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/jazz-pharmaceuticals-signs-exclusive-licensing-deal-with-saniona-for-san2355-development/ 2025-08-22T11:06:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/jazz-pharmaceuticals.jpg http://www.pharmajournalist.com/lillys-oral-glp-1-orforglipron-succeeds-in-third-phase-3-trial-paving-way-for-global-obesity-filings/ 2025-08-27T11:29:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/fda-suspends-u-s-license-for-valnevas-chikungunya-vaccine-ixchiq/ 2025-08-27T11:34:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-to-acquire-gilgameshs-bretisilocin-boosting-psychiatry-pipeline-for-depression/ 2025-08-27T11:36:55+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/genentech-and-roche-break-ground-on-new-manufacturing-facility-in-north-carolina/ 2025-08-27T12:32:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/Genentech-Image.jpg http://www.pharmajournalist.com/datroway-approved-in-china-for-previously-treated-hr-her2-metastatic-breast-cancer/ 2025-08-27T12:34:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/eu-approves-twice-yearly-yeytuo-lenacapavir-for-hiv-prevention/ 2025-08-27T12:37:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gilead.jpg http://www.pharmajournalist.com/outlook-therapeutics-issues-fda-review-update-on-ons-5010-for-wet-amd/ 2025-08-29T12:11:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/rinvoq-receives-health-canada-approval-for-giant-cell-arteritis-in-adults/ 2025-08-29T12:14:20+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/hope-biosciences-earns-fda-rmat-status-for-stem-cell-therapy-in-relapsing-remitting-ms/ 2025-08-29T12:17:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/zemcelpro-wins-ec-approval-as-first-cell-therapy-for-blood-cancer-patients-without-suitable-donors/ 2025-08-29T12:19:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/iqvia-and-flagship-pioneering-partner-to-accelerate-breakthroughs-in-life-sciences/ 2025-08-29T12:23:09+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pfizer-and-biontechs-comirnaty-gets-fda-approval-for-seniors-and-high-risk-individuals-ages-5-64/ 2025-08-29T12:25:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/sandoz-launches-rivaroxaban-in-germany-broadening-access-to-antithrombotic-care/ 2025-08-29T12:26:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/heidelberg-pharma-partner-telix-pharmaceuticals-provides-regulatory-update-on-imaging-agent-tlx250-cdx/ 2025-08-29T12:29:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/gilead-partners-with-pepfar-to-provide-twice-yearly-hiv-prevention-to-2-million-people-in-low-income-countries/ 2025-09-05T10:42:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/fda-boosts-rare-disease-drug-development-with-new-evidence-guidelines/ 2025-09-05T10:45:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/novartis-leqvio-achieves-early-ldl-c-goals-with-less-muscle-pain/ 2025-09-05T10:48:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/avadel-expands-sleep-medicine-portfolio-with-exclusive-valiloxybate-license-from-xwpharma/ 2025-09-05T10:50:48+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/health-canada-approves-elahere-for-platinum-resistant-ovarian-cancer/ 2025-09-05T10:53:02+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/quotient-sciences-and-cpi-launch-joint-venture-to-speed-up-rna-drug-development/ 2025-09-05T10:54:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/amgen-to-invest-over-600-million-in-new-science-and-innovation-center-at-u-s-headquarters/ 2025-09-05T10:57:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/boehringers-hernexeos-approved-in-china-as-first-oral-targeted-therapy-for-her2-mutant-advanced-nsclc/ 2025-09-05T11:00:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/sanofis-wayrilz-approved-in-us-as-first-btk-inhibitor-for-immune-thrombocytopenia/ 2025-09-05T11:02:40+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/santhera-partners-with-ikris-pharma-network-to-distribute-agamree-in-india/ 2025-09-05T11:05:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-leqembi-iqlik-subcutaneous-injection-for-early-alzheimers-maintenance-therapy/ 2025-09-05T11:07:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/EISAI.jpg http://www.pharmajournalist.com/argo-biopharma-secures-multi-asset-license-and-option-deals-with-novartis-for-cardiovascular-drug-candidates/ 2025-09-05T11:10:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/lillys-olomorasib-gets-fda-breakthrough-therapy-nod-for-new-metastatic-kras-g12c-lung-cancer-treatment/ 2025-09-05T11:12:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/illumina-protein-prep-launches-to-boost-proteomic-insights-for-drug-discovery/ 2025-09-05T11:16:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/fda-approves-henlius-and-organons-bildyos-and-bilprevda-biosimilars-to-prolia-and-xgeva/ 2025-09-05T11:18:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/omass-therapeutics-partners-with-genentech-to-develop-inflammatory-bowel-disease-therapies/ 2025-09-05T11:19:54+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-completes-acquisition-of-sanofis-ridgefield-nj-site/ 2025-09-05T11:21:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/kashiv-biosciences-and-cristalia-sign-licensing-and-supply-deal-for-omalizumab-biosimilar-in-latin-america/ 2025-09-12T12:05:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/capvaxive-shows-strong-immune-response-in-at-risk-children-and-teens/ 2025-09-12T12:09:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/kriya-secures-320m-series-d-to-advance-gene-therapies-for-chronic-diseases/ 2025-09-12T12:12:32+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/tzield-approved-in-china-as-first-disease-modifying-therapy-for-stage-2-type-1-diabetes/ 2025-09-12T12:14:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/fda-launches-major-crackdown-on-deceptive-drug-advertising/ 2025-09-12T12:17:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/zentiva-announces-sale-from-advent-to-gtcr/ 2025-09-12T12:19:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/kytopen-partners-with-bluewhale-bio-to-transform-cell-therapy-manufacturing/ 2025-09-12T12:21:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/health-canada-approves-bylvay-for-treating-cholestatic-pruritus-in-alagille-syndrome-patients/ 2025-09-12T12:24:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/novartis-to-acquire-tourmaline-bio-boosting-cardiovascular-pipeline-with-pacibekitug-for-ascvd-treatment/ 2025-09-12T12:26:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/lillys-jaypirca-pirtobrutinib-shows-significant-progression-free-survival-benefit-in-treatment-naive-cll-sll/ 2025-09-12T12:28:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/servier-acquires-promising-fragile-x-syndrome-treatment-key-genetic-cause-of-autism/ 2025-09-12T12:30:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/charles-river-expands-oncology-manufacturing-through-new-collaboration-to-boost-cell-and-gene-therapy-rd/ 2025-09-12T12:32:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Charles-River.jpeg http://www.pharmajournalist.com/scipher-medicine-and-maxymune-therapeutics-partner-to-speed-autoimmune-and-inflammatory-disease-target-discovery/ 2025-09-12T12:34:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sanofis-sar402663-granted-fast-track-designation-for-neovascular-amd-in-the-us/ 2025-09-12T12:35:45+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/tevas-emrusolmin-receives-fda-fast-track-designation-for-multiple-system-atrophy-treatment/ 2025-09-12T12:37:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/fda-approves-inlexzo-gemcitabine-intravesical-system-poised-to-transform-treatment-of-certain-bladder-cancers/ 2025-09-12T12:39:12+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/lean-principles-take-center-stage-at-upcoming-lean-cell-gene-therapy-summits-in-boston-and-d-c/ 2025-09-12T12:41:45+00:00 https://pharmajournalist.com/wp-content/uploads/2025/09/Tagline.jpg https://pharmajournalist.com/wp-content/uploads/2025/09/Tagline.jpg http://www.pharmajournalist.com/eu-approves-novo-nordisks-oral-semaglutide-as-first-glp-1-pill-to-cut-heart-risks/ 2025-09-16T11:11:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/atyr-pharma-reports-positive-topline-results-from-phase-3-efzofitimod-sarcoidosis-trial/ 2025-09-16T11:13:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/fda-approves-amneals-sodium-oxybate-oral-solution/ 2025-09-16T11:16:33+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/cadrenal-boosts-anticoagulation-pipeline-with-acquisition-of-exitheras-factor-xia-inhibitors/ 2025-09-16T11:18:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-grants-orphan-drug-status-to-akesos-ligufalimab-for-aml/ 2025-09-16T11:20:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-breakthrough-therapy-designation-to-raludotatug-deruxtecan-for-cdh6-positive-platinum-resistant-ovarian-and-related-cancers/ 2025-09-16T11:22:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/vectory-and-shape-therapeutics-partner-to-develop-aav5-based-vectorized-antibodies-for-neurodegenerative-diseases/ 2025-09-19T11:00:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/biogens-zurzuvae-approved-in-europe-as-first-treatment-for-postpartum-depression/ 2025-09-19T11:03:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/roche-to-acquire-89bio-in-merger-deal-gaining-phase-3-mash-therapy-candidate/ 2025-09-19T11:07:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/mabwell-and-aditum-bio-launch-kalexo-bio-to-develop-sirna-cardiovascular-therapies/ 2025-09-19T11:11:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fujifilm-biotechnologies-expands-partnership-with-argenx-to-include-u-s-manufacturing/ 2025-09-19T11:14:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/09/Fujifilm.jpg http://www.pharmajournalist.com/varmx-teams-up-with-csl-to-develop-novel-coagulation-treatment/ 2025-09-19T11:16:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gsk-to-invest-30-billion-in-u-s-rd-and-manufacturing-over-next-5-years/ 2025-09-19T11:18:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/reunion-neuroscience-closes-series-a-advances-re104-for-generalized-anxiety-disorder/ 2025-09-19T11:20:51+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/novo-nordisk-ozempic-lowers-heart-attack-stroke-and-death-risk-by-23-vs-dulaglutide-in-real-world-study/ 2025-09-19T11:24:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/novo-nordisks-oral-semaglutide-yields-16-6-weight-loss-in-obesity-study/ 2025-09-19T11:27:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/minovia-therapeutics-mnv-201-granted-fda-fast-track-designation-for-myelodysplastic-syndrome/ 2025-09-19T11:30:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/wheeler-bio-and-mindimmune-therapeutics-partner-to-support-alzheimers-prevention-program-miti-101/ 2025-09-19T11:32:23+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/adagene-and-exelixis-expand-safebody-collaboration-to-develop-third-masked-antibody-drug-conjugate/ 2025-09-19T11:34:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-approves-inluriyo-for-advanced-er-her2-esr1-mutated-breast-cancer/ 2025-09-26T12:31:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/harmony-biosciences-shares-phase-3-reconnect-data-on-zyn002-for-fragile-x-syndrome/ 2025-09-26T12:34:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/basilea-secures-barda-contract-for-phase-3-oral-antibiotic-development/ 2025-09-26T12:37:50+00:00 https://pharmajournalist.com/wp-content/uploads/2019/01/Basilea.jpg http://www.pharmajournalist.com/lonzas-synaffix-partners-with-qurient-to-develop-dual-payload-adc/ 2025-09-26T12:39:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/modernas-mnexspike-shows-strong-immune-response-against-lp-8-1-variant-in-humans/ 2025-09-26T12:41:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/moderna-opens-cutting-edge-manufacturing-and-rd-facility-in-the-uk/ 2025-09-26T12:43:01+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/sanofi-boosts-sanofi-ventures-with-625m-to-accelerate-biotech-and-digital-health-investments/ 2025-09-26T12:44:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/roches-giredestrant-shows-significant-progression-free-survival-benefit-in-phase-iii-er-positive-breast-cancer-trial/ 2025-09-26T12:46:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/biogen-provides-regulatory-update-on-high-dose-nusinersen-regimen/ 2025-09-26T12:48:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/us-regulatory-review-update-tolebrutinib-for-non-relapsing-secondary-progressive-ms/ 2025-09-26T12:50:02+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/eli-lilly-expands-innovation-network-with-new-gateway-labs-site-in-san-diego/ 2025-09-26T12:52:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/european-commission-approves-eli-lillys-kisunla-for-early-alzheimers-disease/ 2025-09-26T12:53:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/eli-lilly-to-build-6-5-billion-manufacturing-facility-in-houston-boosting-u-s-drug-production/ 2025-09-26T12:55:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-astrazeneca-and-daiichi-sankyos-enhertu-for-first-line-her2-positive-metastatic-breast-cancer/ 2025-09-26T12:57:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/tegmine-therapeutics-partners-with-boehringer-ingelheim-to-develop-next-gen-targeted-cancer-therapies/ 2025-09-26T12:59:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/merck-and-siemens-extend-strategic-partnership-to-drive-digital-transformation-in-life-sciences/ 2025-09-26T13:01:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/european-commission-approves-serviers-voranigo-for-treatment-of-grade-2-idh-mutant-glioma/ 2025-09-26T13:04:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/biostar-pharmas-utidelone-receives-third-orphan-drug-designation-from-fda-for-pancreatic-cancer/ 2025-09-26T13:05:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/cellectar-biosciences-partners-with-evestia-clinical-for-phase-1b-trial-of-clr-125-in-triple-negative-breast-cancer/ 2025-09-26T13:07:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.png http://www.pharmajournalist.com/er-kim-and-sentynl-therapeutics-partner-to-expand-access-to-rare-disease-treatments-in-emea-and-eurasian-markets/ 2025-09-26T13:08:23+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/takeda-ends-cell-therapy-program-amid-strategic-refocus/ 2025-10-03T09:06:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/abbvie-begins-70-million-biologics-expansion-in-massachusetts/ 2025-10-03T09:09:40+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/abbvie-logo.jpg http://www.pharmajournalist.com/pfizer-reaches-landmark-agreement-with-u-s-government-to-lower-drug-costs-for-american-patients/ 2025-10-03T09:13:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/klotho-to-acquire-turn-bio-assets-in-300m-longevity-deal/ 2025-10-03T09:16:16+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/halozyme-to-acquire-elektrofi-in-750m-biologics-delivery-deal/ 2025-10-03T09:18:28+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/star-therapeutics-raises-125m-to-advance-bleeding-disorder-drug/ 2025-10-03T09:21:06+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-approves-tremfya-for-pediatric-psoriasis-and-psoriatic-arthritis/ 2025-10-03T09:22:59+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/china-approves-leqembi-iv-maintenance-dosing-for-early-alzheimers/ 2025-10-03T09:26:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/genmab-to-acquire-merus-in-8-billion-deal-to-bolster-cancer-pipeline/ 2025-10-03T09:27:45+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/Genmab-Logo.jpg http://www.pharmajournalist.com/fda-approves-evkeeza-for-youngest-children-with-rare-genetic-cholesterol-disorder/ 2025-10-03T09:29:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/amgen-to-invest-650-million-in-u-s-manufacturing-expansion-creating-nearly-750-jobs/ 2025-10-03T09:31:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/astrazeneca-and-daiichi-sankyos-enhertu-shows-strong-phase-iii-results-in-her2-positive-early-breast-cancer/ 2025-10-03T09:33:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/fda-grants-breakthrough-therapy-designation-to-tayshas-gene-therapy-for-rett-syndrome/ 2025-10-03T09:34:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-fast-track-designation-to-bristol-myers-squibbs-alzheimers-antibody-bms-986446/ 2025-10-03T09:36:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/benchsci-and-thermo-fisher-team-up-to-boost-ai-driven-research-tools/ 2025-10-03T09:38:10+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/labcorp-partners-with-roche-to-advance-digital-pathology-with-fda-cleared-slide-scanners/ 2025-10-03T09:40:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/abbvie-breaks-ground-on-new-api-manufacturing-plant-in-illinois/ 2025-10-03T09:42:16+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/dyne-therapeutics-dyne-251-gains-orphan-drug-status-in-japan-for-duchenne-muscular-dystrophy/ 2025-10-03T09:44:03+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Dyne-Therapeutics-Logo.jpg http://www.pharmajournalist.com/novartis-rhapsido-approved-by-fda-as-first-oral-btk-inhibitor-for-chronic-spontaneous-urticaria/ 2025-10-03T09:45:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/biolinerx-and-hemispherian-form-joint-venture-to-develop-novel-glioblastoma-therapy/ 2025-10-03T09:48:43+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/arthrosi-therapeutics-secures-153-million-in-series-e-financing-to-advance-late-stage-gout-treatment/ 2025-10-09T10:12:43+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-approves-regenerons-libtayo-as-first-adjuvant-immunotherapy-for-high-risk-cscc/ 2025-10-09T10:14:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/affinia-therapeutics-secures-40-million-to-advance-first-in-class-gene-therapy-for-rare-heart-disease/ 2025-10-09T10:16:32+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/oragenics-partners-with-receptor-ai-to-expand-neurological-drug-pipeline-using-ai-powered-discovery/ 2025-10-09T10:17:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/nanophoria-bioscience-secures-e83-5-million-series-a-to-advance-novel-heart-failure-therapy/ 2025-10-09T10:19:46+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-lifts-clinical-hold-on-neurizon-therapeutics-als-drug-nuz-001-clearing-path-for-phase-2-3-trial/ 2025-10-09T10:21:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/chiesi-group-and-arbor-biotechnologies-partner-to-advance-gene-editing-therapies-for-rare-liver-diseases/ 2025-10-09T10:22:22+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/datroway-becomes-first-therapy-to-improve-survival-over-chemotherapy-in-hard-to-treat-triple-negative-breast-cancer/ 2025-10-09T10:23:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/fda-approves-roches-tecentriq-and-lurbinectedin-combo-as-first-maintenance-therapy-for-advanced-small-cell-lung-cancer/ 2025-10-09T10:25:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/werewolf-therapeutics-receives-fda-fast-track-designation-for-wtx-124-in-advanced-melanoma/ 2025-10-09T10:27:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/algen-biotechnologies-and-astrazeneca-partner-to-accelerate-immunology-drug-discovery-using-ai-and-crispr/ 2025-10-09T10:29:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/lean-cell-gene-summit-series-expands-following-successful-boston-debut-next-event-to-take-place-in-national-harbor-md-november-6-2025/ 2025-10-09T10:58:16+00:00 https://pharmajournalist.com/wp-content/uploads/2025/10/LeanSummit_09-22-2025-50.jpg https://pharmajournalist.com/wp-content/uploads/2025/10/LeanSummit_09-22-2025-74.jpg https://pharmajournalist.com/wp-content/uploads/2025/10/LeanSummit_09-22-2025-50.jpg https://pharmajournalist.com/wp-content/uploads/2025/10/LeanSummit_09-22-2025-39.jpg https://pharmajournalist.com/wp-content/uploads/2025/10/LeanSummit_09-22-2025-28.jpg http://www.pharmajournalist.com/turbine-and-astrazeneca-partner-to-advance-adc-discovery-with-virtual-models/ 2025-10-10T09:54:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-boehringer-ingelheims-jascayd-as-first-pde4b-inhibitor-for-idiopathic-pulmonary-fibrosis/ 2025-10-10T09:55:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/cidaras-cd388-receives-fda-breakthrough-therapy-designation-for-flu-prevention-in-high-risk/ 2025-10-10T09:57:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-celltrions-eydenzelt-a-biosimilar-to-eylea-for-multiple-retinal-diseases/ 2025-10-10T09:59:03+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/celltrion-Image.png http://www.pharmajournalist.com/jacobio-sells-80-stake-in-cardiovascular-subsidiary-to-oceanpine-for-rmb-200m/ 2025-10-16T08:41:47+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/pfizers-tukysa-shows-strong-results-in-first-line-her2-breast-cancer-trial/ 2025-10-16T08:43:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/nabla-bio-and-takeda-expand-ai-drug-discovery-deal-worth-over-1b/ 2025-10-16T08:44:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/biocryst-to-acquire-astria-therapeutics-in-700m-deal-to-strengthen-hae-pipeline/ 2025-10-16T08:46:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/biocryst-pharma.jpg http://www.pharmajournalist.com/johnson-johnson-to-spin-off-orthopaedics-unit-as-standalone-company-depuy-synthes/ 2025-10-16T08:47:41+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/fda-expands-rinvoq-use-for-ulcerative-colitis-and-crohns-disease-patients/ 2025-10-16T08:50:17+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/systimmune-begins-global-trial-for-iza-bren-in-breast-cancer-triggers-250m-milestone-from-bms/ 2025-10-16T09:00:23+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-approves-once-monthly-uzedy-for-maintenance-treatment-of-bipolar-i-disorder/ 2025-10-16T09:02:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/avantor-partners-with-bluewhale-bio-to-accelerate-car-t-therapy-manufacturing/ 2025-10-16T09:03:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/viatris-acquires-aculys-pharma-to-expand-cns-portfolio-in-japan/ 2025-10-16T09:05:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/minovia-therapeutics-wins-fda-orphan-drug-designation-for-mnv-201-in-myelodysplastic-syndrome/ 2025-10-16T09:06:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/adcytherix-secures-e105m-series-a-to-advance-cancer-drug-pipeline/ 2025-10-17T12:58:49+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/novo-nordisk-acquires-rights-to-zaltenibart-in-2-1b-rare-disease-deal-with-omeros/ 2025-10-17T13:01:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/tubulis-raises-e308m-to-advance-antibody-drug-conjugate-pipeline/ 2025-10-17T13:03:50+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/merck-partners-with-u-s-government-to-slash-ivf-drug-prices-expand-access/ 2025-10-17T13:05:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/lundbeck-and-contera-partner-to-develop-rna-based-neurology-drugs/ 2025-10-21T10:54:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/lundbeck-logo.jpg http://www.pharmajournalist.com/fda-approves-roches-gazyva-for-lupus-nephritis-with-streamlined-dosing/ 2025-10-21T10:55:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/roches-tecentriq-extends-survival-in-bladder-cancer-using-ctdna-guided-approach/ 2025-10-21T10:57:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/fda-approves-glaukos-epioxa-first-incision-free-drug-for-keratoconus/ 2025-10-21T10:59:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/just-announced-ai-in-drug-discovery-2026-agenda/ 2025-10-21T11:06:34+00:00 https://pharmajournalist.com/wp-content/uploads/2025/10/AI-in-Drug-Discovery-SAE-Media.png http://www.pharmajournalist.com/gsk-and-viiv-healthcare-pledge-6-million-to-boost-global-fight-against-hiv-tb-and-malaria/ 2025-10-24T10:36:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/ema-backs-approval-of-gsks-shingrix-in-new-prefilled-syringe-format/ 2025-10-24T10:37:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/fda-approves-gsks-blenrep-combo-for-relapsed-or-refractory-multiple-myeloma/ 2025-10-24T10:38:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/takeda-and-innovent-partner-in-1-2-billion-deal-to-advance-late-stage-cancer-drugs-globally/ 2025-10-24T10:40:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/ipsen-to-acquire-imcheck-therapeutics-to-boost-immuno-oncology-pipeline/ 2025-10-24T10:41:08+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/alkermes-to-acquire-avadel-in-2-1-billion-deal-to-expand-into-sleep-medicine-market/ 2025-10-24T10:43:35+00:00 https://pharmajournalist.com/wp-content/uploads/2019/02/Alkermes.png http://www.pharmajournalist.com/roches-giredestrant-combo-cuts-breast-cancer-progression-risk-by-up-to-62-in-phase-iii-trial/ 2025-10-24T10:45:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/fda-approves-roches-gazyva-for-lupus-nephritis-offering-new-hope-for-patients/ 2025-10-24T10:46:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/roches-tecentriq-shows-survival-benefit-in-ctdna-guided-bladder-cancer-trial/ 2025-10-24T10:48:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/ventus-therapeutics-teams-up-with-genentech-for-ai-driven-drug-discovery-collaboration/ 2025-10-24T10:49:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/targeted-partnering-licensing-summit-asia-global-exposure-local-advantage/ 2025-10-29T09:38:23+00:00 https://pharmajournalist.com/wp-content/uploads/2025/10/Targeted-Therapies-Partnering-Licensing-Summit-Asia.png http://www.pharmajournalist.com/lifecore-and-polypeptide-partner-to-deliver-end-to-end-peptide-drug-development-solutions-in-the-u-s/ 2025-10-29T09:41:36+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/hemab-therapeutics-secures-157-million-series-c-to-advance-breakthrough-treatments-for-rare-bleeding-disorders/ 2025-10-29T09:43:56+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-expands-approval-of-mercks-winrevair-for-pulmonary-arterial-hypertension-following-strong-phase-3-results/ 2025-10-29T09:45:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/guardant-health-and-zephyr-ai-partner-to-advance-cancer-drug-development-through-ai-driven-insights/ 2025-10-29T09:46:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gsk-acquires-exclusive-rights-to-syndivias-next-generation-adc-for-advanced-prostate-cancer/ 2025-10-29T09:48:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/eli-lilly-to-acquire-adverum-biotechnologies-in-1-5-billion-deal-to-advance-gene-therapy-for-vision-loss/ 2025-10-29T09:49:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/novartis-completes-acquisition-of-tourmaline-bio-to-strengthen-cardiovascular-pipeline/ 2025-10-29T09:51:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/kazia-to-seek-fda-feedback-on-conditional-approval-pathway-for-paxalisib-in-newly-diagnosed-glioblastoma/ 2025-10-29T09:52:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ai-in-drug-discovery-2026-novo-nordisks-peter-clark-to-chair-landmark-event-driving-ai-integration-in-pharma/ 2025-10-30T12:29:26+00:00 https://pharmajournalist.com/wp-content/uploads/2025/10/AI-in-Drug-Discovery-SAE-Media.png http://www.pharmajournalist.com/debiopharm-and-nettargets-partner-to-develop-ai-driven-dual-payload-cancer-therapies/ 2025-10-31T13:24:55+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/eu-approves-alexions-koselugo-for-adults-with-neurofibromatosis-type-1/ 2025-10-31T13:26:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/fda-moves-to-streamline-biosimilar-development-cut-costs-and-speed-access-to-affordable-biologic-alternatives/ 2025-10-31T13:28:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/novo-nordisk-makes-6-5-billion-unsolicited-bid-to-acquire-biotech-firm-metsera/ 2025-10-31T13:30:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/eli-lilly-to-invest-1-2-billion-in-puerto-rico-manufacturing-expansion/ 2025-10-31T13:31:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-designation-to-dewpoint-therapeutics-first-in-class-gastric-cancer-drug/ 2025-10-31T13:33:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/helex-raises-3-5-million-seed-round-to-advance-gene-therapy-for-genetic-kidney-diseases/ 2025-10-31T13:34:24+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/seres-therapeutics-receives-3-6-million-carb-x-grant-to-develop-liquid-form-of-ser-155-for-infection-prevention/ 2025-10-31T13:36:04+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/ucb-secures-fda-approval-for-kygevvi-the-first-ever-treatment-for-ultra-rare-tk2-deficiency/ 2025-11-04T10:10:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/intocell-and-xcellon-biologics-partner-to-advance-next-generation-adc-development-and-manufacturing/ 2025-11-04T10:12:25+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/eli-lilly-to-invest-3-billion-in-new-manufacturing-facility-in-the-netherlands/ 2025-11-04T10:13:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/cencora-to-invest-1-billion-in-expanding-u-s-pharmaceutical-distribution-network-by-2030/ 2025-11-06T10:49:43+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/avant-technologies-and-sgaustria-form-joint-venture-to-develop-stem-cell-based-diabetes-therapy/ 2025-11-06T10:52:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/merck-secures-700-million-from-blackstone-to-advance-cancer-drug-development/ 2025-11-06T10:55:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/pacira-biosciences-partners-with-amacathera-to-develop-long-acting-non-opioid-pain-therapy/ 2025-11-06T10:57:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-designation-to-leukogenes-aml-therapy-lti-214/ 2025-11-06T10:59:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-clears-jupiter-neurosciences-ind-to-launch-phase-2a-trial-of-jotrol-for-parkinsons-disease/ 2025-11-06T11:03:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-johnson-johnsons-darzalex-faspro-as-first-treatment-for-high-risk-smoldering-multiple-myeloma/ 2025-11-07T13:22:56+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/novo-nordisk-showcases-oasis-4-data-highlighting-broader-health-benefits-of-oral-semaglutide-25-mg/ 2025-11-07T13:24:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/abzena-and-mabqi-form-strategic-partnership-to-accelerate-antibody-drug-development/ 2025-11-07T13:26:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/alvotech-and-advanz-pharma-secure-uk-approval-for-gobivaz-a-biosimilar-to-simponi/ 2025-11-07T13:28:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/lyell-immunopharma-boosts-solid-tumor-pipeline-with-acquisition-of-promising-car-t-therapy-for-colorectal-cancer/ 2025-11-11T14:48:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.png http://www.pharmajournalist.com/novartis-opens-new-radioligand-therapy-manufacturing-facility-in-california-to-boost-u-s-cancer-treatment-capacity/ 2025-11-11T14:50:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/harbour-biomed-evinova-partner-to-advance-ai-driven-biologic-drug-development/ 2025-11-11T14:52:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pelthos-acquires-u-s-rights-to-xepi-cream-secures-18m-financing-to-relaunch-product/ 2025-11-11T14:54:29+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/sanegenebio-partners-with-eli-lilly-in-1-2-billion-rnai-metabolic-disease-collaboration/ 2025-11-11T14:57:03+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/insilico-medicine-expands-ai-drug-discovery-partnership-with-eli-lilly-in-100m-collaboration/ 2025-11-11T14:59:02+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/meiragtx-partners-with-eli-lilly-in-475m-gene-therapy-deal-to-restore-vision-in-children/ 2025-11-11T15:00:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/mangoceuticals-launches-direct-glp-1-access-programs-for-affordable-weight-loss-care/ 2025-11-14T13:48:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/uk-approves-monthly-maintenance-dosing-for-alzheimers-drug-leqembi/ 2025-11-14T13:49:47+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/EISAI.jpg http://www.pharmajournalist.com/fda-approval-of-komzifti-marks-major-step-for-hard-to-treat-aml/ 2025-11-14T13:52:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-abbvies-epkinly-combination-for-relapsed-or-refractory-follicular-lymphoma/ 2025-11-19T14:24:32+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/eu-approves-first-ever-treatment-for-non-cystic-fibrosis-bronchiectasis/ 2025-11-19T14:26:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/solve-therapeutics-raises-120m-to-advance-next-generation-adc-platform/ 2025-11-19T14:28:38+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/merus-and-halozyme-partner-to-develop-subcutaneous-version-of-petosemtamab/ 2025-11-19T14:29:55+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/johnson-johnson-to-acquire-halda-therapeutics-for-3-05b-to-expand-oncology-pipeline/ 2025-11-19T14:31:25+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/ema-panel-backs-high-dose-spinraza-regimen-for-spinal-muscular-atrophy/ 2025-11-19T14:33:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/fda-updates-safety-label-for-elevidys-gene-therapy-for-duchenne-muscular-dystrophy/ 2025-11-19T14:34:21+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Sarepta-Therapeutics.jpg http://www.pharmajournalist.com/sofinnova-partners-closes-e650m-fund-to-boost-next-generation-biotech-and-medtech-startups/ 2025-11-19T14:36:26+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/lnp-innovation-surges-as-5th-lnp-summit-unveils-2026-agenda/ 2025-11-19T14:44:43+00:00 https://pharmajournalist.com/wp-content/uploads/2025/11/LNP-US-Pharma-J.png http://www.pharmajournalist.com/ec-approves-first-simponi-biosimilar-gobivaz-in-europe/ 2025-11-21T12:05:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/eu-approves-first-subcutaneous-version-of-keytruda-for-all-adult-indications/ 2025-11-21T12:06:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/mercks-two-drug-hiv-regimen-meets-phase-3-trial-goals/ 2025-11-21T12:08:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/moderna-expands-u-s-manufacturing-with-new-onshore-drug-product-facility/ 2025-11-21T12:10:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/fda-approves-expanded-dosing-options-for-regenerons-eylea-hd-in-retinal-diseases/ 2025-11-21T12:11:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/novartis-to-build-major-u-s-manufacturing-hub-in-north-carolina/ 2025-11-21T12:13:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/eu-grants-conditional-approval-for-roches-one-minute-subcutaneous-lunsumio-in-follicular-lymphoma/ 2025-11-21T12:16:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/alkermes-boosts-offer-to-acquire-avadel-in-deal-worth-up-to-2-37-billion/ 2025-11-21T12:17:34+00:00 https://pharmajournalist.com/wp-content/uploads/2019/02/Alkermes.png http://www.pharmajournalist.com/fda-approves-arrowheads-redemplo-the-first-sirna-therapy-for-familial-chylomicronemia-syndrome/ 2025-11-21T12:19:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/jj-to-acquire-halda-therapeutics-in-3-05b-cancer-therapy-deal/ 2025-11-21T12:24:04+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/genprex-secures-u-s-patent-protecting-reqorsa-and-pd-l1-antibody-combination/ 2025-11-21T12:26:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/fda-approves-first-gene-therapy-for-broad-sma-patient-population/ 2025-11-25T10:05:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/astrazeneca-to-invest-2-billion-in-major-maryland-expansion/ 2025-11-25T10:11:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/vaximm-enters-talks-for-global-license-of-oral-cancer-therapy/ 2025-11-25T10:13:38+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/novo-nordisk-alzheimers-trials-show-no-benefit-for-semaglutide/ 2025-11-25T10:15:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/made-scientific-cellergy-partner-to-advance-first-mitochondrial-therapy/ 2025-11-25T10:16:30+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/telix-opens-first-apac-radiopharmaceutical-manufacturing-site-in-japan/ 2025-11-25T10:19:23+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/Telix-Pharmaceuticals-Logo.jpg http://www.pharmajournalist.com/final-days-to-save-200-on-ai-in-drug-discovery-2026-registration-offer-ends-5-december/ 2025-11-26T12:09:34+00:00 https://pharmajournalist.com/wp-content/uploads/2025/10/AI-in-Drug-Discovery-SAE-Media.png http://www.pharmajournalist.com/fda-names-tracy-beth-hoeg-as-acting-director-of-drug-evaluation-center/ 2025-12-04T12:29:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/agc-biologics-expands-cell-line-center-with-atum-partnership/ 2025-12-04T12:30:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/citizen-health-and-ucb-launch-ai-driven-partnership-for-rare-diseases/ 2025-12-04T12:31:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/fda-proposes-new-guidance-to-reduce-non-human-primate-testing/ 2025-12-04T12:32:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/formosa-pharmaceuticals-grants-rxilient-rights-to-new-ophthalmic-drug/ 2025-12-04T12:34:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-expands-approval-of-lillys-jaypirca-for-earlier-cll-sll-treatment/ 2025-12-04T12:35:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/fda-grants-rare-pediatric-disease-status-to-solid-biosciences-fa-therapy/ 2025-12-04T12:37:00+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/solid-biosciences.jpg http://www.pharmajournalist.com/lotus-files-south-korea-nda-for-lenzs-presbyopia-drug-vizz/ 2025-12-04T12:38:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/regeneron-tessera-partner-on-gene-writing-therapy-for-aatd/ 2025-12-04T12:39:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/lupin-wins-fda-approval-for-armlupeg-pegfilgrastim-biosimilar/ 2025-12-04T12:41:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/lupin-pharma.jpg http://www.pharmajournalist.com/fda-grants-breakthrough-status-to-ionis-drug-for-alexander-disease/ 2025-12-04T12:42:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/ionis-pharma1.jpg http://www.pharmajournalist.com/iqvia-partners-with-aws-to-advance-agentic-ai-in-life-sciences/ 2025-12-04T12:43:35+00:00 https://pharmajournalist.com/wp-content/uploads/2018/12/IQVIA-Logo.png http://www.pharmajournalist.com/fda-grants-breakthrough-status-to-ionis-olezarsen-for-shtg/ 2025-12-04T12:45:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/ionis-pharma1.jpg http://www.pharmajournalist.com/stay-ahead-in-rnai-join-80-leaders-shaping-2026-innovation/ 2025-12-05T13:32:52+00:00 https://pharmajournalist.com/wp-content/uploads/2025/11/RNAi-Banner-Pharma-J.png http://www.pharmajournalist.com/china-approves-two-sanofi-drugs-for-rare-blood-disorders/ 2025-12-12T10:49:04+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/moderna-nanexa-sign-deal-to-develop-long-acting-injectable-medicines/ 2025-12-12T10:50:49+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/china-approves-first-new-progressive-pulmonary-fibrosis-drug-in-5-years/ 2025-12-12T10:52:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/formation-bio-acquires-global-rights-to-next-gen-tyk2-inhibitor/ 2025-12-12T10:53:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/zealand-pharma-and-otr-therapeutics-launch-collaboration-on-metabolic-drugs/ 2025-12-12T10:54:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/zydus-formycon-partner-to-bring-keytruda-biosimilar-to-north-america/ 2025-12-12T10:57:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/pfizer-reports-strong-phase-3-results-for-tukysa-in-her2-breast-cancer/ 2025-12-12T10:59:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/eu-approves-roches-gazyva-for-advanced-lupus-nephritis-treatment/ 2025-12-12T11:00:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/inductive-bio-wins-21m-to-build-ai-drug-toxicity-models/ 2025-12-12T11:01:23+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/viatris-sells-biocon-biologics-stake-for-815m-in-strategic-shift/ 2025-12-12T11:03:17+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/pfizer-yaopharma-partner-on-glp-1-drug-for-weight-management/ 2025-12-12T11:05:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/telix-and-varian-partner-to-advance-theranostic-driven-cancer-care/ 2025-12-12T11:07:07+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/Telix-Pharmaceuticals-Logo.jpg http://www.pharmajournalist.com/fda-grants-breakthrough-designation-to-adrabetadex-for-infantile-npc/ 2025-12-12T11:08:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-status-to-ajaxs-aj1-11095-for-myelofibrosis/ 2025-12-12T11:09:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-amneals-epinephrine-vials-for-emergency-and-hospital-use/ 2025-12-12T11:10:37+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/lilly-invests-6-billion-in-alabama-facility-for-next-generation-medicines/ 2025-12-12T11:11:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/takeda-reports-strong-phase-3-results-for-oral-psoriasis-therapy/ 2025-12-19T12:30:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/fda-approves-first-subcutaneous-therapy-for-egfr-mutated-lung-cancer/ 2025-12-19T12:32:30+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/phase-3-trial-shows-survival-gains-in-muscle-invasive-bladder-cancer/ 2025-12-19T12:34:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/alnylam-expands-massachusetts-facility-to-advance-rnai-manufacturing/ 2025-12-19T12:36:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/fda-approves-gsks-twice-yearly-biologic-for-severe-eosinophilic-asthma/ 2025-12-19T12:38:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/harbour-biomed-bristol-myers-squibb-partner-on-multi-specific-antibodies/ 2025-12-19T12:40:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/takeda-protagonist-file-nda-for-rusfertide-in-polycythemia-vera/ 2026-01-06T11:53:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/fda-grants-priority-review-for-tzield-pediatric-indication-expansion/ 2026-01-06T11:55:04+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/insilico-medicine-servier-partner-on-ai-driven-oncology-drug-discovery/ 2026-01-06T11:56:39+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/china-accepts-bla-for-subcutaneous-leqembi-formulation/ 2026-01-06T11:58:23+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/samsung-bioepis-begins-direct-byooviz-commercialization-in-europe/ 2026-01-06T11:59:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/canada-approves-arrowheads-redemplo-for-rare-triglyceride-disorder/ 2026-01-06T12:01:41+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/arrowhead-pharma-logo.jpg http://www.pharmajournalist.com/fda-issues-complete-response-letter-for-outlooks-wet-amd-therapy/ 2026-01-06T12:03:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/china-approves-zai-labs-augtyro-for-ntrk-fusion-solid-tumors/ 2026-01-07T09:35:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/fda-grants-expedited-status-to-protaras-pediatric-lymphatic-malformation-therapy/ 2026-01-07T09:36:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/takeda-expands-entyvio-options-through-halozyme-technology-partnership/ 2026-01-09T11:07:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/gsk-phase-iii-trials-show-promise-for-chronic-hepatitis-b-therapy/ 2026-01-09T11:08:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/fda-approves-new-2-gram-fibryga-kit-for-bleeding-care/ 2026-01-09T11:10:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/day-one-completes-acquisition-of-mersana-therapeutics/ 2026-01-09T11:12:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/amgen-acquires-dark-blue-to-advance-novel-aml-treatments/ 2026-01-09T11:14:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/lilly-to-acquire-ventyx-in-1-2-billion-inflammation-deal/ 2026-01-09T11:16:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/lilly-trial-shows-dual-therapy-benefits-in-psoriatic-arthritis-patients/ 2026-01-09T11:17:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/santhera-licenses-agamree-to-nxera-in-key-asia-pacific-markets/ 2026-01-09T11:19:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png